

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in (therapeutic protein) drug... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-113/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-113" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in (therapeutic protein) drug development" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in (therapeutic protein) drug development.">
            <meta name="og:description" content="Read the latest article version by H.A. Daniel Lagass&eacute;, Aikaterini Alexaki, Vijaya L. Simhadri, Nobuko H. Katagiri, Wojciech Jankowski, Zuben E. Sauna, Chava Kimchi-Sarfaty, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="10745">
            <meta name="article-id" content="9970">
            <meta name="dc.title" content="Recent advances in (therapeutic protein) drug development">
            <meta name="dc.description" content="Therapeutic protein drugs are an important class of medicines serving patients most in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, autoimmunity/inflammation, exposure to infectious agents, and genetic disorders. The latest advances in protein-engineering technologies have allowed drug developers and manufacturers to fine-tune and exploit desirable functional characteristics of proteins of interest while maintaining (and in some cases enhancing) product safety or efficacy or both. In this review, we highlight the emerging trends and approaches in protein drug development by using examples of therapeutic proteins approved by the U.S. Food and Drug Administration over the previous five years (2011&ndash;2016, namely January 1, 2011, through August 31, 2016).">
            <meta name="dc.subject" content="therapeutic protein drugs, protein therapeutics, cancer therapeutics, biosimilar, recombinant DNA-derived therapeutic proteins, ">
            <meta name="dc.creator" content="Lagass&eacute;, H.A. Daniel">
            <meta name="dc.creator" content="Alexaki, Aikaterini">
            <meta name="dc.creator" content="Simhadri, Vijaya L.">
            <meta name="dc.creator" content="Katagiri, Nobuko H.">
            <meta name="dc.creator" content="Jankowski, Wojciech">
            <meta name="dc.creator" content="Sauna, Zuben E.">
            <meta name="dc.creator" content="Kimchi-Sarfaty, Chava">
            <meta name="dc.date" content="2017/02/07">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.9970.1">
            <meta name="dc.source" content="F1000Research 2017 6:113">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="therapeutic protein drugs">
            <meta name="prism.keyword" content="protein therapeutics">
            <meta name="prism.keyword" content="cancer therapeutics">
            <meta name="prism.keyword" content="biosimilar">
            <meta name="prism.keyword" content="recombinant DNA-derived therapeutic proteins">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/02/07">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="113">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.9970.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-113">
            <meta name="citation_title" content="Recent advances in (therapeutic protein) drug development">
            <meta name="citation_abstract" content="Therapeutic protein drugs are an important class of medicines serving patients most in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, autoimmunity/inflammation, exposure to infectious agents, and genetic disorders. The latest advances in protein-engineering technologies have allowed drug developers and manufacturers to fine-tune and exploit desirable functional characteristics of proteins of interest while maintaining (and in some cases enhancing) product safety or efficacy or both. In this review, we highlight the emerging trends and approaches in protein drug development by using examples of therapeutic proteins approved by the U.S. Food and Drug Administration over the previous five years (2011&ndash;2016, namely January 1, 2011, through August 31, 2016).">
            <meta name="citation_description" content="Therapeutic protein drugs are an important class of medicines serving patients most in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, autoimmunity/inflammation, exposure to infectious agents, and genetic disorders. The latest advances in protein-engineering technologies have allowed drug developers and manufacturers to fine-tune and exploit desirable functional characteristics of proteins of interest while maintaining (and in some cases enhancing) product safety or efficacy or both. In this review, we highlight the emerging trends and approaches in protein drug development by using examples of therapeutic proteins approved by the U.S. Food and Drug Administration over the previous five years (2011&ndash;2016, namely January 1, 2011, through August 31, 2016).">
            <meta name="citation_keywords" content="therapeutic protein drugs, protein therapeutics, cancer therapeutics, biosimilar, recombinant DNA-derived therapeutic proteins, ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="H.A. Daniel Lagass&eacute;">
            <meta name="citation_author_institution" content="Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA">
            <meta name="citation_author" content="Aikaterini Alexaki">
            <meta name="citation_author_institution" content="Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA">
            <meta name="citation_author" content="Vijaya L. Simhadri">
            <meta name="citation_author_institution" content="Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA">
            <meta name="citation_author" content="Nobuko H. Katagiri">
            <meta name="citation_author_institution" content="Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA">
            <meta name="citation_author" content="Wojciech Jankowski">
            <meta name="citation_author_institution" content="Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA">
            <meta name="citation_author" content="Zuben E. Sauna">
            <meta name="citation_author_institution" content="Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA">
            <meta name="citation_author" content="Chava Kimchi-Sarfaty">
            <meta name="citation_author_institution" content="Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA">
            <meta name="citation_publication_date" content="2017/02/07">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="113">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.9970.1">
            <meta name="citation_firstpage" content="113">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-113/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-113.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=10745 /> <input type=hidden id=articleId name=articleId value=9970 /> <input type=hidden id=xmlUrl value="/articles/6-113/v1/xml"/> <input type=hidden id=xmlFileName value="-6-113-v1.xml"> <input type=hidden id=article_uuid value=3fb32563-5249-488d-8956-4afa0bd4251f /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in (therapeutic protein) drug development"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.9970.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.9970.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-113"
  },
  "headline": "Recent advances in (therapeutic protein) drug development",
  "datePublished": "2017-02-07T14:11:35",
  "dateModified": "2017-02-07T14:11:35",
  "author": [
    {
      "@type": "Person",
      "name": "H.A. Daniel Lagass&eacute;"
    },    {
      "@type": "Person",
      "name": "Aikaterini Alexaki"
    },    {
      "@type": "Person",
      "name": "Vijaya L. Simhadri"
    },    {
      "@type": "Person",
      "name": "Nobuko H. Katagiri"
    },    {
      "@type": "Person",
      "name": "Wojciech Jankowski"
    },    {
      "@type": "Person",
      "name": "Zuben E. Sauna"
    },    {
      "@type": "Person",
      "name": "Chava Kimchi-Sarfaty"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Therapeutic protein drugs are an important class of medicines serving patients most in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, autoimmunity/inflammation, exposure to infectious agents, and genetic disorders. The latest advances in protein-engineering technologies have allowed drug developers and manufacturers to fine-tune and exploit desirable functional characteristics of proteins of interest while maintaining (and in some cases enhancing) product safety or efficacy or both. In this review, we highlight the emerging trends and approaches in protein drug development by using examples of therapeutic proteins approved by the U.S. Food and Drug Administration over the previous five years (2011&ndash;2016, namely January 1, 2011, through August 31, 2016)."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-113.html",
            "name": "Recent advances in (therapeutic protein) drug development"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in (therapeutic protein) drug development </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=10745 data-id=9970 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9970.1" data-recommended="" data-doi="10.12688/f1000research.9970.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-113/v1/pdf?article_uuid=3fb32563-5249-488d-8956-4afa0bd4251f" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-9970-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-9970-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-9970-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Lagassé HAD, Alexaki A, Simhadri VL <em>et al.</em> Recent advances in (therapeutic protein) drug development [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):113 (<a class=new-orange href="https://doi.org/10.12688/f1000research.9970.1" target=_blank>https://doi.org/10.12688/f1000research.9970.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-9970-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=9970 id=track-article-signin-9970 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9970?target=/articles/6-113.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10745 /> <input name=articleId type=hidden value=9970 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in (therapeutic protein) drug development</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">H.A. Daniel Lagass&eacute;,&nbsp;</span><span class="">Aikaterini Alexaki,&nbsp;</span><span class="">Vijaya L. Simhadri,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Nobuko H. Katagiri,&nbsp;</span><span class="">Wojciech Jankowski,&nbsp;</span><span class=""><a href="mailto:Zuben.Sauna@fda.hhs.gov" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Zuben E. Sauna</span></a>,&nbsp;</span><span class=""><a href="mailto:Chava.kimchi-sarfaty@fda.hhs.gov" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Chava Kimchi-Sarfaty</span></a><a href="https://orcid.org/0000-0002-9355-8585" target=_blank id=author-orcid-6><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-6><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-9355-8585</div></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">H.A. Daniel Lagass&eacute;,&nbsp;</span><span class="">Aikaterini Alexaki,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Vijaya L. Simhadri,&nbsp;</span><span class=article-page-hidden-authors>Nobuko H. Katagiri,&nbsp;</span><span class=article-page-hidden-authors>Wojciech Jankowski,&nbsp;</span><span class=""><a href="mailto:Zuben.Sauna@fda.hhs.gov" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Zuben E. Sauna</span></a>,&nbsp;</span><span class=""><a href="mailto:Chava.kimchi-sarfaty@fda.hhs.gov" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Chava Kimchi-Sarfaty</span></a><a href="http://orcid.org/0000-0002-9355-8585" target=_blank id=mauthor-orcid-6><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-6><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-9355-8585</div></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 07 Feb 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.9970.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=19878-19529></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=18172-19530></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Therapeutic protein drugs are an important class of medicines serving patients most in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, autoimmunity/inflammation, exposure to infectious agents, and genetic disorders. The latest advances in protein-engineering technologies have allowed drug developers and manufacturers to fine-tune and exploit desirable functional characteristics of proteins of interest while maintaining (and in some cases enhancing) product safety or efficacy or both. In this review, we highlight the emerging trends and approaches in protein drug development by using examples of therapeutic proteins approved by the U.S. Food and Drug Administration over the previous five years (2011–2016, namely January 1, 2011, through August 31, 2016). </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> therapeutic protein drugs, protein therapeutics, cancer therapeutics, biosimilar, recombinant DNA-derived therapeutic proteins, </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Zuben E. Sauna (<a href="mailto:Zuben.Sauna@fda.hhs.gov">Zuben.Sauna@fda.hhs.gov</a>) <br> Chava Kimchi-Sarfaty (<a href="mailto:Chava.kimchi-sarfaty@fda.hhs.gov">Chava.kimchi-sarfaty@fda.hhs.gov</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Zuben E. Sauna, Chava Kimchi-Sarfaty </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Lagassé HAD <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Lagassé HAD, Alexaki A, Simhadri VL <em>et al.</em> Recent advances in (therapeutic protein) drug development [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):113 (<a href="https://doi.org/10.12688/f1000research.9970.1" target=_blank>https://doi.org/10.12688/f1000research.9970.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 07 Feb 2017, <b>6</b>(F1000 Faculty Rev):113 (<a href="https://doi.org/10.12688/f1000research.9970.1" target=_blank>https://doi.org/10.12688/f1000research.9970.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 07 Feb 2017, <b>6</b>(F1000 Faculty Rev):113 (<a href="https://doi.org/10.12688/f1000research.9970.1" target=_blank>https://doi.org/10.12688/f1000research.9970.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d89253e228>Protein engineering</h2><p class="" id=d89253e231>The manufacturing and production of therapeutic proteins are highly complex processes<sup><a href="#ref-1">1</a>–<a href="#ref-3">3</a></sup>. For example, a typical protein drug may include in excess of 5,000 critical process steps, many times greater than the number required for manufacturing a small-molecule drug<sup><a href="#ref-4">4</a></sup> (<a href="#f1">Figure 1a</a>).</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/10745/caf27ffc-4640-428b-82de-df53149fc3b5_figure1.gif"><img alt="caf27ffc-4640-428b-82de-df53149fc3b5_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/10745/caf27ffc-4640-428b-82de-df53149fc3b5_figure1.gif"></a><div class=caption><h3>Figure 1. Complexity of therapeutic protein drugs.</h3><p id=d89253e258>(<b>a</b>) Graphical representation of the complexity of the manufacture of a therapeutic protein drug compared with a small-molecule drug. The number of batch records, product quality tests, critical process steps, and process data entries associated with small-molecule drugs (black) and therapeutic protein drugs (grey) as bars<sup><a href="#ref-4">4</a></sup>. (<b>b</b>) Illustration depicting the differences in size and complexity of a protein therapeutic (recombinant (r) analogue of human coagulation factor VIII (FVIII); Novoeight, Novo Nordisk; molecular weight = 166,000 Da) and a small-molecule drug (ibuprofen; molecular weight = 206 Da) by molecular model.</p></div></div><p class="" id=d89253e275>Similarly, protein therapeutics, which include monoclonal antibodies as well as large or fusion proteins, can be orders-of-magnitude larger in size than small-molecule drugs, having molecular weights exceeding 100 kDa (<a href="#f1">Figure 1b</a>). In addition, protein therapeutics exhibit complex secondary and tertiary structures that must be maintained. Protein therapeutics cannot be completely synthesized by chemical processes and have to be manufactured in living cells or organisms; consequently, the choices of the cell line, species origin, and culture conditions all affect the final product characteristics<sup><a href="#ref-5">5</a>–<a href="#ref-7">7</a></sup>. Moreover, most biologically active proteins require post-translational modifications that can be compromised when heterologous expression systems are used. Additionally, as the products are synthesized by cells or organisms, complex purification processes are involved. Furthermore, viral clearance processes such as removal of virus particles by using filters or resins, as well as inactivation steps by using low pH or detergents, are implemented to prevent the serious safety issue of viral contamination of protein drug substances<sup><a href="#ref-8">8</a></sup>. Given the complexity of therapeutic proteins with respect to their large molecular size, post-translational modifications, and the variety of biological materials involved in their manufacturing process, the ability to enhance particular functional attributes while maintaining product safety and efficacy achieved through protein-engineering strategies is highly desirable.</p><p class="" id=d89253e292>While the integration of novel strategies and approaches to modify protein drug products is not a trivial matter<sup><a href="#ref-9">9</a></sup>, the potential therapeutic advantages have driven the increased use of such strategies during drug development. A number of protein-engineering platform technologies are currently in use to increase the circulating half-life, targeting, and functionality of novel therapeutic protein drugs as well as to increase production yield and product purity (<a href="#T1">Table 1</a>)<sup><a href="#ref-5">5</a>–<a href="#ref-7">7</a>,<a href="#ref-10">10</a>–<a href="#ref-12">12</a></sup>. For example, protein conjugation and derivatization approaches, including Fc-fusion<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>, albumin-fusion<sup><a href="#ref-15">15</a></sup>, and PEGylation<sup><a href="#ref-16">16</a></sup>, are currently being used to extend a drug’s circulating half-life<sup><a href="#ref-17">17</a></sup>. Longer <i>in vivo</i> half-lives are of particular importance to patients undergoing factor/enzyme/hormone replacement therapy, in which frequent dosing regimens can result in substantial negative impacts on patient well-being in terms of ease of administration and compliance, especially in young children<sup><a href="#ref-18">18</a></sup>. Protein-engineering approaches have also been employed to target drugs through the addition of signaling peptides or the generation of antibody-drug conjugates<sup><a href="#ref-19">19</a></sup>, thereby limiting toxicity and increasing drug efficacy. Additionally, exploiting particular functional characteristics of a protein drug can be accomplished through protein engineering. For example, influencing a protein’s glycosylation pattern through engineering strategies can impact the protein’s receptor-binding properties and overall effector function<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup>. In <a href="#T1">Table 1</a>, we have highlighted a few examples of the many technological innovations and protein-engineering platform technologies incorporated by recently approved therapeutic proteins.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Protein-engineering platform technologies.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d89253e369 class=n-a></a><thead><a name=d89253e371 class=n-a></a><tr><a name=d89253e373 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e375 class=n-a></a>Platform technology</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e378 class=n-a></a>Example of U.S. Food and Drug Administration-approved therapeutic protein</th></tr></thead><tbody><a name=d89253e383 class=n-a></a><tr><a name=d89253e385 class=n-a></a><td align=left colspan=2 rowspan=1 valign=top><a name=d89253e387 class=n-a></a>Protein production technologies</td></tr><tr><a name=d89253e391 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e393 class=n-a></a>Production of proteins in transgenic<br class=br>animals<sup><a href="#ref-46">46</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e401 class=n-a></a>C1 esterase inhibitor (Ruconest) produced in transgenic rabbit milk<sup><a href="#ref-47">47</a></sup></td></tr><tr><a name=d89253e408 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e410 class=n-a></a>Production of proteins in transgenic<br class=br>plants<sup><a href="#ref-48">48</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e418 class=n-a></a>Human glucocerebrosidase (Elelyso) produced in carrot root cells<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup></td></tr><tr><a name=d89253e428 class=n-a></a><td align=left colspan=2 rowspan=1 valign=top><a name=d89253e430 class=n-a></a>Rational protein structure/function technologies</td></tr><tr><a name=d89253e434 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e436 class=n-a></a>Glyco-engineering<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e445 class=n-a></a>Humanized anti-CD20 monoclonal antibody (Gazyva)<sup><a href="#ref-51">51</a></sup></td></tr><tr><a name=d89253e453 class=n-a></a><td align=left colspan=1 rowspan=6 valign=top><a name=d89253e455 class=n-a></a>Fc fusion<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e464 class=n-a></a>VEGFR Fc-fusion (Eylea)</td></tr><tr><a name=d89253e468 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e470 class=n-a></a>CTLA-4 Fc-fusion (Nulojix)</td></tr><tr><a name=d89253e474 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e476 class=n-a></a>Glucagon-like peptide-<br class=br>1 receptor agonist Fc-fusion (Trulicity)</td></tr><tr><a name=d89253e482 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e484 class=n-a></a>VEGFR Fc-fusion (Zaltrap)</td></tr><tr><a name=d89253e488 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e490 class=n-a></a>Recombinant factor IX Fc fusion (Alprolix)<sup><a href="#ref-52">52</a></sup></td></tr><tr><a name=d89253e497 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e499 class=n-a></a>Recombinant factor VIII Fc-fusion (Eloctate)<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup></td></tr><tr><a name=d89253e510 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d89253e512 class=n-a></a>Albumin fusion<sup><a href="#ref-15">15</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e518 class=n-a></a>GLP-1 receptor agonist-albumin fusion (Tanzeum)</td></tr><tr><a name=d89253e522 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e524 class=n-a></a>Recombinant factor IX albumin fusion (Idelvion)</td></tr><tr><a name=d89253e528 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d89253e530 class=n-a></a>PEGylation<sup><a href="#ref-55">55</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e536 class=n-a></a>PEGylated IFNβ-1a (Plegridy)</td></tr><tr><a name=d89253e540 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e542 class=n-a></a>Recombinant factor VIII PEGylated (Adynovate)</td></tr><tr><a name=d89253e546 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d89253e548 class=n-a></a>Antibody-drug conjugates<sup><a href="#ref-19">19</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e554 class=n-a></a>Humanized anti-HER2/neu conjugated to emtansine (Kadcyla)</td></tr><tr><a name=d89253e558 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e560 class=n-a></a>Mouse/human chimeric anti-CD30 (Adcetris)</td></tr><tr><a name=d89253e565 class=n-a></a><td align=left colspan=1 rowspan=14 valign=top><a name=d89253e567 class=n-a></a>mAb humanization/chimerism</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e570 class=n-a></a>Humanized mAbs</td></tr><tr><a name=d89253e574 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e576 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-human epidermal growth factor receptor 2 (HER2) (Perjeta)</td></tr><tr><a name=d89253e580 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e582 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-HER2/neu conjugated to emtansine (Kadcyla)</td></tr><tr><a name=d89253e586 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e588 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-IL-6 receptor (Actemra)</td></tr><tr><a name=d89253e592 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e594 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-CD20 (obinutuzumab; Gazyva)</td></tr><tr><a name=d89253e598 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e600 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-integrin a4b7 (LPAM-1) (Entyvio)</td></tr><tr><a name=d89253e605 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e607 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-PD-1 (Keytruda)</td></tr><tr><a name=d89253e611 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e613 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-dabigatran (Praxbind)</td></tr><tr><a name=d89253e617 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e619 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-IL-5 (Nucala)</td></tr><tr><a name=d89253e623 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e625 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-CD319 (SLAMF7) (Empliciti)</td></tr><tr><a name=d89253e629 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e631 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-IL-17a (Taltz)</td></tr><tr><a name=d89253e635 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e637 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-IL-5 (Cinqair)</td></tr><tr><a name=d89253e642 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e644 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-PD-L1 (Tecentriq)</td></tr><tr><a name=d89253e648 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e650 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-CD25 (Zinbryta)</td></tr><tr><a name=d89253e654 class=n-a></a><td align=left colspan=1 rowspan=7><a name=d89253e656 class=n-a></a></td></tr><tr><a name=d89253e659 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e661 class=n-a></a>Mouse/human chimeric mAbs</td></tr><tr><a name=d89253e665 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e667 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-CD30 (Adcetris)</td></tr><tr><a name=d89253e671 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e673 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-IL-6 (Sylvant)</td></tr><tr><a name=d89253e678 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e680 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-GD2 (Unituxin)</td></tr><tr><a name=d89253e684 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e686 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-<i>Bacillus anthracis</i> (Anthim)</td></tr><tr><a name=d89253e693 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e695 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-TNFα (Inflectra)</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d89253e703 class=n-a></a><p id=d89253e705> Listing of commonly used protein-engineering platform technologies and examples of U.S. Food and Drug Administration-approved therapeutic proteins (2011–2016, namely January 1, 2011, through August 31, 2016) that employ each strategy. CD, cluster of differentiation; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; Fc, fragment crystallizable; GD2, disialoganglioside; GLP-1, glucagon-like peptide-1; HER2, human epidermal growth factor receptor 2; IFNb, interferon beta; IL, interleukin; LPAM-1, lymphocyte Peyer’s Patch adhesion molecule; mAb, monoclonal antibody; PD-1, programmed death receptor-1; PD-L1, programmed death-ligand 1; PEG, polyethylene glycol; SLAMF7, SLAM family member 7; TNFα, tumor necrosis factor alpha; VEGFR, vascular endothelial growth factor receptor.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d89253e714>Overview of recently approved protein therapeutics (2011–2016*)</h2><p class="" id=d89253e717>Since 2011, the U.S. Food and Drug Administration Center for Drug Evaluation and Review (CDER) and the Center for Biologics Evaluation and Review (CBER) combined have approved 62 recombinant therapeutic proteins (*January 1, 2011, through August 31, 2016; “Purple Book” list of licensed biological products, including biosimilar and interchangeable biological products<sup><a href="#ref-22">22</a></sup>) (<a href="#f2">Figure 2a</a>). Of these 62 therapeutic proteins, almost half (48%) were monoclonal antibodies (for this analysis, we included antibody-drug conjugates and antibody fragment antigen binding in this group). Coagulation factors were the next largest class (19%) of approved protein drugs over this time period. Replacement enzymes comprised 11% of all approvals. Remaining approvals (22%) were divided among fusion proteins, hormones, growth factors, and plasma proteins (<a href="#f2">Figure 2b</a>). These U.S. Food and Drug Administration (FDA)-approved therapeutic proteins are indicated for a wide variety of therapeutic areas. Over half of the approved therapeutic proteins were indicated for oncology (26%) and hematology (29%), whereas the remaining 45% had primary indications in cardiology/vascular disease (5%), dermatology (3%), endocrinology (6%), gastroenterology (2%), genetic disease (2%), immunology (6%), infectious diseases (3%), musculoskeletal (8%), nephrology (2%), ophthalmology (3%), pulmonary/respiratory disease (3%), and rheumatology (2%) (<a href="#f2">Figure 2c</a>, left). Of the 16 oncology drugs, six were approved to treat hematologic malignancies, whereas the remaining therapeutics were indicated for dermatology (3), gastroenterology (2), obstetrics/gynecology (2), pediatrics (1), pulmonary/respiratory disease (1), and urology (1) (<a href="#f2">Figure 2c</a>, right). For a complete listing of the approved products, see <a href="#T2">Table 2</a>. It is evident that recently approved therapeutic proteins serve a wide spectrum of patient populations and are of great benefit to public health.</p><div class="fig panel clearfix"><a name=f2 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/10745/caf27ffc-4640-428b-82de-df53149fc3b5_figure2.gif"><img alt="caf27ffc-4640-428b-82de-df53149fc3b5_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/10745/caf27ffc-4640-428b-82de-df53149fc3b5_figure2.gif"></a><div class=caption><h3>Figure 2. U.S. Food and Drug Administration (FDA)-approved therapeutic proteins (2011–2016*).</h3><p id=d89253e750>(<b>a</b>) Bar graph showing the number of therapeutic protein FDA approvals by year (2011–2016*). (<b>b</b>) Pie chart showing the distribution of FDA-approved therapeutic proteins (2011–2016*) by drug class. (<b>c</b>) (Left) Pie chart showing the distribution of FDA-approved therapeutic proteins (2011–2016*) by therapeutic area. (Right) Pie chart showing the distribution of secondary therapeutic area for oncology drugs. *January 1, 2011, through August 31, 2016.</p></div></div><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. U.S. Food and Drug Administration-approved protein therapeutics (2011–2016).</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d89253e777 class=n-a></a><thead><a name=d89253e779 class=n-a></a><tr><a name=d89253e781 class=n-a></a><th align=center colspan=4 rowspan=1><a name=d89253e783 class=n-a></a>CDER approved protein therapeutics [2011–2016*]</th></tr><tr><a name=d89253e787 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e789 class=n-a></a>#<br class=br>Approval<br class=br>Date</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e796 class=n-a></a>Drug<br class=br>[Market Name; Sponsor]</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e801 class=n-a></a>Class<br class=br>[Description]</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e806 class=n-a></a>Therapeutic Area<br class=br>[General Indication]</th></tr></thead><tbody><a name=d89253e813 class=n-a></a><tr><a name=d89253e815 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e817 class=n-a></a> <b>1</b> <br class=br>3/9/2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e825 class=n-a></a>belimumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125460s000lbl.pdf" id=d89253e829>Benlysta</a>; Human<br class=br>Genome Sciences]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e835 class=n-a></a>mAb<br class=br>[human anti-B-cell activating<br class=br>factor (BAFF)]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e842 class=n-a></a>immunology<br class=br>[autoimmunity (lupus)]</td></tr><tr><a name=d89253e848 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e850 class=n-a></a> <b>2</b> <br class=br>3/25/2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e858 class=n-a></a>ipilimumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf" id=d89253e862>Yervoy</a>; Bristol Myers<br class=br>Squibb]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e868 class=n-a></a>mAb<br class=br>[human anti-CTLA-4]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e873 class=n-a></a>dermatology/oncology<br class=br>[cancer (melanoma)]</td></tr><tr><a name=d89253e879 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e881 class=n-a></a> <b>3</b> <br class=br>6/15/2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e889 class=n-a></a>belatacept<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125288s062lbl.pdf" id=d89253e893>Nulojix</a>; Bristol Myers<br class=br>Squibb]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e899 class=n-a></a>Fc fusion<br class=br>[CTLA-4 Fc-fusion]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e904 class=n-a></a>immunology/nephrology<br class=br>[transplant rejection (kidney)]</td></tr><tr><a name=d89253e910 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e912 class=n-a></a> <b>4</b> <br class=br>8/19/2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e920 class=n-a></a>brentuximab vedotin<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125388s084lbl.pdf" id=d89253e924>Adcetris</a>; Seattle Genetics]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e928 class=n-a></a>antibody-drug conjugate<br class=br>[mouse/human chimeric anti-<br class=br>CD30]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e935 class=n-a></a>hematology/oncology<br class=br>[cancer (lymphoma)]</td></tr><tr><a name=d89253e941 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e943 class=n-a></a> <b>5</b> <br class=br>11/18/2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e951 class=n-a></a>afilbercept<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125387s051lbl.pdf" id=d89253e955>Eylea</a>; Regeneron<br class=br>Pharmaceuticals]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e961 class=n-a></a>Fc fusion<br class=br>[VEGFR Fc-fusion]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e966 class=n-a></a>ophthalmology<br class=br>[macular degeneration]</td></tr><tr><a name=d89253e973 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e975 class=n-a></a> <b>6</b> <br class=br>11/18/2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e983 class=n-a></a>asparaginase erwinia<br class=br>chrysanthemi<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125359s088lbl.pdf" id=d89253e989>Erwinaze</a>; Jazz<br class=br>Pharmaceuticals]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e995 class=n-a></a>enzyme<br class=br>[asparaginase erwinia<br class=br>chrysanthemi]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1002 class=n-a></a>hematology/oncology<br class=br>[cancer (leukemia)]</td></tr><tr><a name=d89253e1008 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1010 class=n-a></a> <b>7</b> <br class=br>1/17/2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1018 class=n-a></a>glucarpidase<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf" id=d89253e1022>Voraxaze</a>; BTG<br class=br>International]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1028 class=n-a></a>enzyme<br class=br>[glucarpidase]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1033 class=n-a></a>nephrology<br class=br>[kidney failure]</td></tr><tr><a name=d89253e1039 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1041 class=n-a></a> <b>8</b> <br class=br>5/1/2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1049 class=n-a></a>taliglucerase alfa<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022458s012lbl.pdf" id=d89253e1053>Elelyso</a>; Pfizer]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1057 class=n-a></a>enzyme<br class=br>[β-glucocerebrosidase]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1062 class=n-a></a>endocrinology/gastroenterology<br class=br>[genetic disorder (Gaucher)]</td></tr><tr><a name=d89253e1068 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1070 class=n-a></a> <b>9</b><br class=br>6/8/2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1077 class=n-a></a>pertuzumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125409s109lbl.pdf" id=d89253e1081>Perjeta</a>; Genentech]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1085 class=n-a></a>mAb<br class=br>[humanized anti-human<br class=br>epidermal growth factor<br class=br>receptor 2 (HER2)]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1094 class=n-a></a>obstetrics, gynecology/oncology<br class=br>[cancer (breast)]</td></tr><tr><a name=d89253e1100 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1102 class=n-a></a> <b>10</b> <br class=br>8/3/2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1110 class=n-a></a>ziv-afilbercept<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125418s039lbl.pdf" id=d89253e1114>Zaltrap</a>; Sanofi-Aventis<br class=br>U.S.]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1120 class=n-a></a>Fc fusion<br class=br>[VEGFR Fc fusion]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1125 class=n-a></a>gastroenterology/oncology<br class=br>[cancer (colorectal)]</td></tr><tr><a name=d89253e1131 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1133 class=n-a></a> <b>11</b> <br class=br>8/29/2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1141 class=n-a></a>tbo-filgrastim<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125294s035lbl.pdf" id=d89253e1145>Granix</a>; Cephalon]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1149 class=n-a></a>growth factor<br class=br>[G-CSF]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1154 class=n-a></a>hematology/oncology<br class=br>[neutropenia]</td></tr><tr><a name=d89253e1161 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1163 class=n-a></a> <b>12</b> <br class=br>10/17/2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1171 class=n-a></a>ocriplasmin<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125422s037lbl.pdf" id=d89253e1175>Jetrea</a>; ThromboGenics]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1179 class=n-a></a>enzyme<br class=br>[ocriplasmin]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1184 class=n-a></a>ophthalmology<br class=br>[eye condition (symptomatic vitreomacular<br class=br>adhesion)]</td></tr><tr><a name=d89253e1192 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1194 class=n-a></a> <b>13</b> <br class=br>12/14/2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1202 class=n-a></a>raxibacumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125349s000lbl.pdf" id=d89253e1206>raxibacumab</a>; Human<br class=br>Genome Sciences]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1212 class=n-a></a>mAb<br class=br>[human anti-anthrax protective<br class=br>antigen (PA)]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1219 class=n-a></a>infections and infectious disease<br class=br>[infectious disease (inhalational anthrax)]</td></tr><tr><a name=d89253e1225 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1227 class=n-a></a> <b>14</b> <br class=br>2/22/2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1235 class=n-a></a>ado-trastuzumab<br class=br>emtansine<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125427s096lbl.pdf" id=d89253e1241>Kadcyla</a>; Genentech]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1245 class=n-a></a>antibody-drug conjugate<br class=br>[humanized anti-HER2/neu<br class=br>conjugated to emtansine]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1252 class=n-a></a>obstetrics, gynecology/oncology<br class=br>[cancer (breast)]</td></tr><tr><a name=d89253e1258 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1260 class=n-a></a> <b>15</b> <br class=br>7/18/2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1268 class=n-a></a>golimumab injection, for<br class=br>IV use<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125433s018lbl.pdf" id=d89253e1274>Simponi Aria</a>; Janssen<br class=br>Biotech]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1280 class=n-a></a>mAb<br class=br>[human anti-TNFα]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1285 class=n-a></a>musculoskeletal/rheumatology<br class=br>[autoimmunity (rheumatoid arthritis)]</td></tr><tr><a name=d89253e1291 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1293 class=n-a></a> <b>16</b> <br class=br>10/21/2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1301 class=n-a></a>tocilizumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125472s000lbl.pdf" id=d89253e1305>Actemra</a>; Genentech]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1309 class=n-a></a>mAb<br class=br>[humanized anti-IL-6 receptor]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1314 class=n-a></a>musculoskeletal/rheumatology<br class=br>[autoimmunity (rheumatoid arthritis;<br class=br>juvenile idiopathic arthritis)]</td></tr><tr><a name=d89253e1322 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1324 class=n-a></a> <b>17</b> <br class=br>11/1/2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1332 class=n-a></a>obinutuzumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125486s013lbl.pdf" id=d89253e1336>Gazyva</a>; Genentech]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1340 class=n-a></a>mAb<br class=br>[humanized anti-CD20]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1345 class=n-a></a>hematology/oncology<br class=br>[cancer (leukemia)]</td></tr><tr><a name=d89253e1352 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1354 class=n-a></a> <b>18</b> <br class=br>2/14/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1362 class=n-a></a>elosulfase alfa<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125460s000lbl.pdf" id=d89253e1366>Vimizim</a>; BioMarin<br class=br>Pharmaceutical]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1372 class=n-a></a>enzyme<br class=br>[elosulfase alfa]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1377 class=n-a></a>musculoskeletal/genetic disease<br class=br>[genetic disorder (Morquio A)]</td></tr><tr><a name=d89253e1383 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1385 class=n-a></a> <b>19</b> <br class=br>2/24/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1393 class=n-a></a>metreleptin<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125390s010lbl.pdf" id=d89253e1397>Myalept</a>; Amylin<br class=br>Pharmaceuticals]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1403 class=n-a></a>hormone<br class=br>[metreleptin]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1408 class=n-a></a>immunology<br class=br>[lipodystrophy]</td></tr><tr><a name=d89253e1414 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1416 class=n-a></a> <b>20</b> <br class=br>4/15/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1424 class=n-a></a>albiglutide<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125431s009lbl.pdf" id=d89253e1428>Tanzeum</a>;<br class=br>GlaxoSmithKline]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1434 class=n-a></a>albumin fusion/hormone<br class=br>[glucagon-like peptide-1<br class=br>dimer albumin fusion]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1441 class=n-a></a>endocrinology<br class=br>[diabetes (type 2)]</td></tr><tr><a name=d89253e1447 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1449 class=n-a></a> <b>21</b> <br class=br>4/21/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1457 class=n-a></a>ramucirumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125477s011lbl.pdf" id=d89253e1461>Cyramza</a>; Eli Lilly and<br class=br>Company]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1467 class=n-a></a>mAb<br class=br>[human anti-VEGFR2 (KDR)]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1472 class=n-a></a>gastroenterology/oncology<br class=br>[cancer (stomach; gastroesophageal<br class=br>junction)]</td></tr><tr><a name=d89253e1480 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1482 class=n-a></a> <b>22</b> <br class=br>4/23/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1490 class=n-a></a>siltuximab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf" id=d89253e1494>Sylvant</a>; Janssen<br class=br>Biotech]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1500 class=n-a></a>mAb<br class=br>[mouse/human chimeric anti-<br class=br>IL-6]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1507 class=n-a></a>hematology/immunology<br class=br>[multicentric Castleman's disease]</td></tr><tr><a name=d89253e1513 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1515 class=n-a></a> <b>23</b> <br class=br>5/20/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1523 class=n-a></a>vedolizumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf" id=d89253e1527>Entyvio</a>; Takeda<br class=br>Pharmaceuticals<br class=br>America]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1535 class=n-a></a>mAb<br class=br>[humanized anti-integrin a4b7<br class=br>(lymphocyte Peyer's Patch<br class=br>adhesion molecule; LPAM-1)]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1544 class=n-a></a>gastroenterology/immunology<br class=br>[inflammatory (ulcerative colitis/Crohn's<br class=br>disease)]</td></tr><tr><a name=d89253e1553 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1555 class=n-a></a> <b>24</b> <br class=br>8/15/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1563 class=n-a></a>peginterferon beta-1a<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125499s011lbl.pdf" id=d89253e1567>Plegridy</a>; Biogen Idec]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1571 class=n-a></a>cytokine<br class=br>[PEGylated IFNb-1b]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1576 class=n-a></a>immunology/musculoskeletal<br class=br>[multiple sclerosis]</td></tr><tr><a name=d89253e1582 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1584 class=n-a></a> <b>25</b> <br class=br>9/4/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1592 class=n-a></a>pembrolizumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s009lbl.pdf" id=d89253e1596>Keytruda</a>; Merck Sharp<br class=br>&amp; Dohme]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1602 class=n-a></a>mAb<br class=br>[humanized anti-PD-1]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1607 class=n-a></a>dermatology/oncology<br class=br>[cancer (melanoma)]</td></tr><tr><a name=d89253e1613 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1615 class=n-a></a> <b>26</b> <br class=br>9/18/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1623 class=n-a></a>dulaglutide<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000Lbl.pdf" id=d89253e1627>Trulicity</a>; Eli Lilly and<br class=br>Company]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1633 class=n-a></a>Fc fusion<br class=br>[glucagon-like peptide-1<br class=br>receptor agonist]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1640 class=n-a></a>endocrinology<br class=br>[diabetes (type 2)]</td></tr><tr><a name=d89253e1646 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1648 class=n-a></a> <b>27</b> <br class=br>12/3/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1656 class=n-a></a>blintumomab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125557s005s006lbl.pdf" id=d89253e1660>Blincyto</a>; Amgen]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1664 class=n-a></a>mAb<br class=br>[mouse bispecific anti-CD19/<br class=br>anti-CD3]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1671 class=n-a></a>hematology/oncology<br class=br>[cancer (leukemia)]</td></tr><tr><a name=d89253e1677 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1679 class=n-a></a> <b>28</b> <br class=br>12/22/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1687 class=n-a></a>nivolumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125554s019lbl.pdf" id=d89253e1691>Opdivo</a>; Bristol Myers<br class=br>Squibb]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1697 class=n-a></a>mAb<br class=br>[human anti-PD-1]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1702 class=n-a></a>dermatology/oncology<br class=br>[cancer (melanoma)]</td></tr><tr><a name=d89253e1708 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1710 class=n-a></a> <b>29</b> <br class=br>1/21/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1718 class=n-a></a>secukinumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf" id=d89253e1722>Cosentyx</a>; Novartis<br class=br>Pharmaceuticals]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1728 class=n-a></a>mAb<br class=br>[human anti-IL-17A]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1733 class=n-a></a>dermatology/immunology<br class=br>[autoimmunity (plaque psoriasis)]</td></tr><tr><a name=d89253e1740 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1742 class=n-a></a> <b>30</b> <br class=br>1/23/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1750 class=n-a></a>parathyroid hormone<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125511s004lbl.pdf" id=d89253e1754>Natpara</a>; NPS<br class=br>Pharmaceuticals]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1760 class=n-a></a>hormone<br class=br>[parathyroid hormone]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1765 class=n-a></a>endocrinology/hematology<br class=br>[hypoparathyroidism]</td></tr><tr><a name=d89253e1771 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1773 class=n-a></a> <b>31</b> <br class=br>3/6/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1781 class=n-a></a>filgrastim-sndz<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125553s001lbl.pdf" id=d89253e1785>Zarxio</a>; Sandoz]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1789 class=n-a></a>growth factor<br class=br>[G-CSF]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1794 class=n-a></a>hematology/oncology<br class=br>[neutropenia]</td></tr><tr><a name=d89253e1800 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1802 class=n-a></a> <b>32</b> <br class=br>3/10/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1810 class=n-a></a>dinutuximab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125516s000lbl.pdf" id=d89253e1814>Unituxin</a>; United<br class=br>Therapeutics]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1820 class=n-a></a>mAb<br class=br>[mouse/human chimeric anti-<br class=br>GD2]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1827 class=n-a></a>oncology/pediatrics/neonatalogy<br class=br>[cancer (neuroblastoma)]</td></tr><tr><a name=d89253e1833 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1835 class=n-a></a> <b>33</b> <br class=br>7/24/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1843 class=n-a></a>alirocumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125559Orig1s000lbledt.pdf" id=d89253e1847>Praluent</a>; Sanofi-Aventis<br class=br>U.S.]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1853 class=n-a></a>mAb<br class=br>[human anti-proprotein<br class=br>convertase substilisin/kexin<br class=br>type 9 (PCSK9)]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1862 class=n-a></a>cardiology/vascular diseases<br class=br>[high cholesterol]</td></tr><tr><a name=d89253e1868 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1870 class=n-a></a> <b>34</b> <br class=br>8/27/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1878 class=n-a></a>evolocumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125522s000lbl.pdf" id=d89253e1882>Repatha</a>; Amgen]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1886 class=n-a></a>mAb<br class=br>[human anti-proprotein<br class=br>convertase substilisin/kexin<br class=br>type 9 (PCSK9)]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1895 class=n-a></a>cardiology/vascular diseases<br class=br>[high cholesterol]</td></tr><tr><a name=d89253e1901 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1903 class=n-a></a> <b>35</b> <br class=br>10/16/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1911 class=n-a></a>idarucizumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf" id=d89253e1915>Praxbind</a>;<br class=br>Boehringer Ingelheim<br class=br>Pharmaceuticals]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1923 class=n-a></a>Fab<br class=br>[humanized anti-dabigatran]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1928 class=n-a></a>hematology<br class=br>[anticoagulant reversal]</td></tr><tr><a name=d89253e1935 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1937 class=n-a></a> <b>36</b> <br class=br>10/23/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1945 class=n-a></a>asfotase-alfa<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125513s000lbl.pdf" id=d89253e1949>Strensiq</a>; Alexion<br class=br>Pharmaceuticals]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1955 class=n-a></a>Fc fusion/enzyme<br class=br>[tissue non-specific alkaline<br class=br>phosphatase/Fc fusion/deca-<br class=br>asparatate (D10) peptide]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1964 class=n-a></a>genetic disease/pediatrics/neonatalogy<br class=br>[genetic disorder (hypophosphatasia)]</td></tr><tr><a name=d89253e1970 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1972 class=n-a></a> <b>37</b> <br class=br>11/4/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1980 class=n-a></a>mepolizumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125526Orig1s000Lbl.pdf" id=d89253e1984>Nucala</a>; GlaxoSmithKline]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1988 class=n-a></a>mAb<br class=br>[humanized anti-IL-5]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e1993 class=n-a></a>pulmonary/respiratory disease<br class=br>[asthma]</td></tr><tr><a name=d89253e1999 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2001 class=n-a></a> <b>38</b> <br class=br>11/16/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2009 class=n-a></a>daratumumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036Orig1s000lbledt.pdf" id=d89253e2013>Darzalex</a>; Janssen<br class=br>Biotech]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2019 class=n-a></a>mAb<br class=br>[human anti-CD38]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2024 class=n-a></a>hematology/oncology<br class=br>[cancer (multiple myeloma)]</td></tr><tr><a name=d89253e2030 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2032 class=n-a></a> <b>39</b> <br class=br>11/24/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2040 class=n-a></a>necitumumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf" id=d89253e2044>Portrazza</a>; Eli Lilly and<br class=br>Company]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2050 class=n-a></a>mAb<br class=br>[human anti-epidermal growth<br class=br>factor receptor (EGFR)]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2057 class=n-a></a>pulmonary/respiratory disease/oncology<br class=br>[cancer (lung)]</td></tr><tr><a name=d89253e2063 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2065 class=n-a></a> <b>40</b> <br class=br>11/30/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2073 class=n-a></a>elotuzumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf" id=d89253e2077>Empliciti</a>; Bristol Myers<br class=br>Squibb]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2083 class=n-a></a>mAb<br class=br>[humanized anti-<br class=br>CD319(SLAMF7)]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2090 class=n-a></a>oncology<br class=br>[cancer (multiple myeloma)]</td></tr><tr><a name=d89253e2096 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2098 class=n-a></a> <b>41</b> <br class=br>12/8/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2106 class=n-a></a>sebelipase alfa<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125561s000lbl.pdf" id=d89253e2110>Kanuma</a>; Alexion<br class=br>Pharmaceuticals]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2116 class=n-a></a>enzyme<br class=br>[lysosomal acid lipase]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2121 class=n-a></a>cardiology/vascular diseases/genetic<br class=br>disease<br class=br>[lysosomal acid lipase deficiency]</td></tr><tr><a name=d89253e2130 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2132 class=n-a></a> <b>42</b> <br class=br>3/18/2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2140 class=n-a></a>obiltoxaximab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125509lbl.pdf" id=d89253e2144>Anthim</a>; Elusys<br class=br>Therapeutics]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2150 class=n-a></a>mAb<br class=br>[mouse/human chimeric anti-<br class=br><i>Bacillus anthracis</i>]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2159 class=n-a></a>infections and infectious disease<br class=br>[infectious disease (inhalational anthrax)]</td></tr><tr><a name=d89253e2165 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2167 class=n-a></a> <b>43</b> <br class=br>3/22/2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2175 class=n-a></a>ixekizumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf" id=d89253e2179>Taltz</a>; Eli Lilly and<br class=br>Company]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2185 class=n-a></a>mAb<br class=br>[humanized anti-IL-17a]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2190 class=n-a></a>dermatology/immunology<br class=br>[autoimmunity (plaque psoriasis)]</td></tr><tr><a name=d89253e2196 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2198 class=n-a></a> <b>44</b> <br class=br>3/23/2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2206 class=n-a></a>reslizumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf" id=d89253e2210>Cinqair</a>; Teva<br class=br>Respiratory]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2216 class=n-a></a>mAb<br class=br>[humanized anti-IL-5]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2221 class=n-a></a>pulmonary/respiratory disease<br class=br>[asthma]</td></tr><tr><a name=d89253e2227 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2229 class=n-a></a> <b>45</b> <br class=br>4/5/2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2237 class=n-a></a>infliximab-dyyb<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125544s000lbl.pdf" id=d89253e2241>Inflectra</a>; Celltrion]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2245 class=n-a></a>mAb<br class=br>[mouse/human chimeric anti-<br class=br>TNFα]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2252 class=n-a></a>musculoskeletal/rheumatology<br class=br>[inflammatory (Crohn's disease/ulcerative<br class=br>colitis/rheumatoid arthritis/ankylosing<br class=br>spondylitis/psoriatic arthritis/plaque<br class=br>psoriasis)]</td></tr><tr><a name=d89253e2264 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2266 class=n-a></a> <b>46</b> <br class=br>5/18/2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2274 class=n-a></a>atezolizumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034Orig1s000lbl.pdf" id=d89253e2278>Tecentriq</a>; Genentech]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2282 class=n-a></a>mAb<br class=br>[humanized anti-PD-L1]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2287 class=n-a></a>urology/oncology<br class=br>[cancer (bladder)]</td></tr><tr><a name=d89253e2293 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2295 class=n-a></a> <b>47</b> <br class=br>5/27/2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2303 class=n-a></a>daclizumab<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761029s000lbl.pdf" id=d89253e2307>Zinbryta</a>; Biogen]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2311 class=n-a></a>mAb<br class=br>[humanized anti-CD25]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2316 class=n-a></a>musculoskeletal/neurology<br class=br>[multiple sclerosis]</td></tr><tr><a name=d89253e2323 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2325 class=n-a></a> <b>48</b> <br class=br>8/30/2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2333 class=n-a></a>etanercept-szzs<br class=br>[<a target=xrefwindow href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761042lbl.pdf" id=d89253e2337>Erelzi</a>; Sandoz]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2341 class=n-a></a>Fc fusion<br class=br>[TNFR Fc-fusion]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2346 class=n-a></a>rheumatology<br class=br>[inflammatory (rheumatoid<br class=br>arthritis/juvenile idiopathic<br class=br>arthritis/psoriatic arthritis/ankylosing<br class=br>spondylitis/plaque psoriasis)]</td></tr><tr><a name=d89253e2358 class=n-a></a><th align=center colspan=4 rowspan=1><a name=d89253e2360 class=n-a></a>CBER approved protein therapeutics [2011–2016*]</th></tr><tr><a name=d89253e2364 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e2366 class=n-a></a>#<br class=br>Approval Date</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e2371 class=n-a></a>Drug Name<br class=br>[Market Name; Sponsor]</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e2376 class=n-a></a>Class<br class=br>Description</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e2381 class=n-a></a>Therapeutic Area</th></tr><tr><a name=d89253e2385 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2387 class=n-a></a> <b>1</b> <br class=br>6/26/2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2395 class=n-a></a>coagulation factor IX<br class=br>recombinant human<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM358875.pdf" id=d89253e2401>Rixubis</a>; Baxter<br class=br>Healthcare]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2407 class=n-a></a>coagulation factor<br class=br>[recombinant factor IX]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2412 class=n-a></a>hematology<br class=br>[hemophilia B]</td></tr><tr><a name=d89253e2418 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2420 class=n-a></a> <b>2</b> <br class=br>10/15/2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2428 class=n-a></a>antihemophilic factor<br class=br>(recombinant)<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM371094.pdf" id=d89253e2434>Novoeight</a>; Novo<br class=br>Nordisk]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2440 class=n-a></a>coagulation factor<br class=br>[recombinant factor VIII]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2445 class=n-a></a>hematology<br class=br>[hemophilia A]</td></tr><tr><a name=d89253e2451 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2453 class=n-a></a> <b>3</b> <br class=br>12/23/2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2461 class=n-a></a>coagulation factor XIII A-<br class=br>subunit (recombinant)<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM379763.pdf" id=d89253e2467>Tretten</a>; Novo Nordisk]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2471 class=n-a></a>coagulation factor<br class=br>[recombinant factor XIII A<br class=br>subunit]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2478 class=n-a></a>hematology<br class=br>[congenital factor XIII deficiency]</td></tr><tr><a name=d89253e2485 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2487 class=n-a></a> <b>4</b> <br class=br>3/28/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2495 class=n-a></a>coagulation factor IX<br class=br>(recombinant), Fc fusion<br class=br>protein<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM391049.pdf" id=d89253e2503>Alprolix</a>; Biogen]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2507 class=n-a></a>Fc fusion/coagulation factor<br class=br>[recombinant factor IX Fc-<br class=br>fusion]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2514 class=n-a></a>hematology<br class=br>[hemophilia B]</td></tr><tr><a name=d89253e2520 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2522 class=n-a></a> <b>5</b> <br class=br>6/6/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2530 class=n-a></a>antihemophilic factor<br class=br>(recombinant), Fc fusion<br class=br>protein<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM400192.pdf" id=d89253e2538>Eloctate</a>; Biogen]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2542 class=n-a></a>Fc fusion/coagulation factor<br class=br>[recombinant factor VIII Fc-<br class=br>fusion]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2549 class=n-a></a>hematology<br class=br>[hemophilia A]</td></tr><tr><a name=d89253e2555 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2557 class=n-a></a> <b>6</b> <br class=br>7/16/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2565 class=n-a></a>C1 esterase inhibitor<br class=br>recombinant<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM405634.pdf" id=d89253e2571>Ruconest</a>; Salix<br class=br>Pharmaceuticals]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2577 class=n-a></a>plasma protein<br class=br>[recombinant C1 esterase<br class=br>inhibitor]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2584 class=n-a></a>hematology<br class=br>[hereditary angioedema]</td></tr><tr><a name=d89253e2590 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2592 class=n-a></a> <b>7</b> <br class=br>10/23/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2600 class=n-a></a>antihemophilic factor<br class=br>porcine, B-domain<br class=br>truncated recombinant<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM420173.pdf" id=d89253e2608>Obizur</a>; Baxter<br class=br>Healthcare]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2614 class=n-a></a>coagulation factor<br class=br>[recombinant factor VIII<br class=br>(porcine)]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2621 class=n-a></a>hematology<br class=br>[hemophilia A]</td></tr><tr><a name=d89253e2627 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2629 class=n-a></a> <b>8</b> <br class=br>4/29/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2637 class=n-a></a>coagulation factor IX<br class=br>(recombinant)<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM445106.pdf" id=d89253e2643>Ixinity</a>; Cangene<br class=br>BioPharma]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2649 class=n-a></a>coagulation factor<br class=br>[recombinant factor IX]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2654 class=n-a></a>hematology<br class=br>[hemophilia B]</td></tr><tr><a name=d89253e2660 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2662 class=n-a></a> <b>9</b> <br class=br>9/4/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2670 class=n-a></a>antihemophilic factor<br class=br>(recombinant)<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM461328.pdf" id=d89253e2676>Nuwiq</a>; Octapharma<br class=br>USA]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2682 class=n-a></a>coagulation factor<br class=br>[recombinant factor VIII]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2687 class=n-a></a>hematology<br class=br>[hemophilia A]</td></tr><tr><a name=d89253e2694 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2696 class=n-a></a> <b>10</b> <br class=br>11/13/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2704 class=n-a></a>antihemophilic factor<br class=br>(recombinant) PEGylated<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM472594.pdf" id=d89253e2710>Adynovate</a>; Baxalta US]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2714 class=n-a></a>coagulation factor<br class=br>[recombinant factor VIII<br class=br>PEGylated]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2721 class=n-a></a>hematology<br class=br>[hemophilia A]</td></tr><tr><a name=d89253e2727 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2729 class=n-a></a> <b>11</b> <br class=br>12/8/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2737 class=n-a></a>von Willebrand factor<br class=br>(recombinant)<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM476176.pdf" id=d89253e2743>Vonvendi</a>; Baxalta US]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2747 class=n-a></a>plasma protein<br class=br>[recombinant VWF]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2752 class=n-a></a>hematology<br class=br>[von Willebrand disease]</td></tr><tr><a name=d89253e2758 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2760 class=n-a></a> <b>12</b> <br class=br>3/4/2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2768 class=n-a></a>coagulation factor IX<br class=br>recombinant human<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM489301.pdf" id=d89253e2774>Idelvion</a>; CSL Behring<br class=br>Recombinant]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2780 class=n-a></a>coagulation factor<br class=br>[recombinant factor IX albumin<br class=br>fusion]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2787 class=n-a></a>hematology<br class=br>[hemophilia B]</td></tr><tr><a name=d89253e2793 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2795 class=n-a></a> <b>13</b> <br class=br>3/16/2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2803 class=n-a></a>antihemophilic factor<br class=br>(recombinant)<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM491118.pdf" id=d89253e2809>Kovaltry</a>; Bayer<br class=br>HealthCare]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2815 class=n-a></a>coagulation factor<br class=br>[recombinant factor VIII full-<br class=br>length]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2822 class=n-a></a>hematology<br class=br>[hemophilia A]</td></tr><tr><a name=d89253e2828 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2830 class=n-a></a> <b>14</b> <br class=br>5/25/2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2838 class=n-a></a>antihemophilic factor<br class=br>(recombinant)<br class=br>[<a target=xrefwindow href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM503560.pdf" id=d89253e2844>Afstyla</a>; CSL Behring]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2848 class=n-a></a>coagulation factor<br class=br>[recombinant factor VIII]</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2853 class=n-a></a>hematology<br class=br>[hemophilia A]</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d89253e2863 class=n-a></a><p id=d89253e2865> Comprehensive listing of all FDA-approved therapeutic proteins granted orphan designation upon original submission from January 1, 2011, through August 31, 2016, listed in chronological order of FDA approval. In addition, the class of protein, a brief description, and orphan designation are included. CD, cluster of differentiation; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; Fab, fragment antigen binding; Fc, fragment crystallizable; GD2, disialoganglioside; IL, interleukin; mAb, monoclonal antibody; PD-1, programmed death receptor-1; VEGFR, vascular endothelial growth factor receptor.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d89253e2874>Pathways for the development of novel therapeutics</h2><p class="" id=d89253e2877>The rapid advances in biomedical science and technology to address unmet medical needs also require that regulatory agencies ensure that such products are safe and effective. Several new pathways have emerged or have been finalized since 2011 and are summarized below (<a href="#T3">Table 3</a>).</p><div class="table-wrap panel clearfix"><a name=T3 class=n-a></a><div class=caption><h3>Table 3. Pathways for the development of novel therapeutics.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d89253e2894 class=n-a></a><thead><a name=d89253e2896 class=n-a></a><tr><a name=d89253e2898 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e2900 class=n-a></a>Pathway</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e2903 class=n-a></a>Description and relevant U.S. Food and Drug Administration (FDA) guidances</th></tr></thead><tbody><a name=d89253e2908 class=n-a></a><tr><a name=d89253e2910 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2912 class=n-a></a>Breakthrough<br class=br>therapy<br class=br>designation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2919 class=n-a></a>“process designed to expedite the development and review of drugs that are intended to treat<br class=br>a serious condition and preliminary clinical evidence indicates that the drug may demonstrate<br class=br>substantial improvement over available therapy on a clinically significant endpoint(s)”<sup><a href="#ref-56">56</a>,<a href="#ref-57">57</a></sup>.<br class=br><br class=br>Guidance for industry:<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expedited Programs for Serious Conditions – Drugs and Biologics<sup><a href="#ref-58">58</a></sup></td></tr><tr><a name=d89253e2943 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2945 class=n-a></a>Orphan<br class=br>designation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2950 class=n-a></a>Rare disease or condition that affects 200,000 people or fewer per year in the U.S.<sup><a href="#ref-59">59</a></sup><br class=br><br class=br>Guidance for industry:<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(<i>Draft</i>) Rare Diseases: Common Issues in Drug Development<sup><a href="#ref-60">60</a></sup></td></tr><tr><a name=d89253e2968 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2970 class=n-a></a>Biosimilar</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e2973 class=n-a></a>‘an abbreviated licensure pathway for biological products that are demonstrated to be<br class=br>“biosimilar” to or “interchangeable” with an FDA-licensed biological product… a biological<br class=br>product may be demonstrated to be “biosimilar” if data show that, among other things, the<br class=br>product is “highly similar” to an already-approved biological product’<sup><a href="#ref-61">61</a></sup>.<br class=br><br class=br>Guidance for industry:<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a Reference Product<sup><a href="#ref-28">28</a></sup><br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scientific Considerations in Demonstrating Biosimilarity to a Reference Product<sup><a href="#ref-27">27</a></sup><br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competition and Innovation Act of 2009<sup><a href="#ref-29">29</a></sup><br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Applicants<sup><a href="#ref-30">30</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d89253e3025 class=n-a></a><p id=d89253e3027> Summary of three pathways for the development of novel therapeutics that have emerged or have been finalized since 2011.</p></div></div></div><div class=section><a name=d89253e3033 class=n-a></a><h3 class=section-title>Breakthrough therapy designation</h3><p class="" id=d89253e3038>The Food and Drug Administration Safety and Innovation Act (FDASIA) was signed on July 9, 2012. FDASIA Section 902 provided the FDA with the ability to establish breakthrough therapy designation (BTD) as a new program within the Expedited Programs for Serious Conditions<sup><a href="#ref-23">23</a></sup>. BTD was designed to be available for drugs intended to treat a serious condition and that have been shown to exhibit initial clinical evidence of considerable improvement over pre-existing therapies. The BTD program joined other expedited development and review programs, including fast track designation (1997), accelerated approval (1992), and priority review designation (1992), which have promoted innovation by facilitating the expedited development and review of novel medicines. Since FDASIA was signed in July 2012, CDER has approved 30 original BTDs, one third (10) of which were protein drugs. Over this same period, 26% of CDER-approved biologics (10 out of 39) have been granted BTD designation (<a href="#T4">Table 4</a>). Since July 2012, CBER has also approved two drugs under the BTD designation, but neither of these was a recombinant protein.</p><div class="table-wrap panel clearfix"><a name=T4 class=n-a></a><div class=caption><h3>Table 4. Therapeutic proteins granted breakthrough therapy designation upon original submission.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d89253e3059 class=n-a></a><thead><a name=d89253e3061 class=n-a></a><tr><a name=d89253e3063 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e3065 class=n-a></a>#</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e3068 class=n-a></a>Approval<br class=br>date</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e3073 class=n-a></a>Drug name<br class=br>(Market name)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e3078 class=n-a></a>Class</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e3081 class=n-a></a>Description</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e3085 class=n-a></a>Use</th></tr></thead><tbody><a name=d89253e3090 class=n-a></a><tr><a name=d89253e3092 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3094 class=n-a></a>1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3097 class=n-a></a>11/1/2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3100 class=n-a></a>Obinutuzumab<br class=br>(Gazyva)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3105 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3108 class=n-a></a>Humanized anti-CD20</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3112 class=n-a></a>Treatment of patients with previously<br class=br>untreated chronic lymphocytic leukemia<br class=br>in combination with chlorambucil</td></tr><tr><a name=d89253e3120 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3122 class=n-a></a>2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3125 class=n-a></a>9/4/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3128 class=n-a></a>Pembrolizumab<br class=br>(Keytruda)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3133 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3136 class=n-a></a>Humanized anti-PD-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3140 class=n-a></a>Treatment of patients with unresectable<br class=br>or metastatic melanoma and disease<br class=br>progression following ipilimumab and,<br class=br>if BRAF V600 mutation positive, a BRAF<br class=br>inhibitor</td></tr><tr><a name=d89253e3152 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3154 class=n-a></a>3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3157 class=n-a></a>12/3/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3160 class=n-a></a>Blinatumomab<br class=br>(Blincyto)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3165 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3168 class=n-a></a>Mouse bispecific anti-<br class=br>CD19/anti-CD3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3174 class=n-a></a>Treatment of Philadelphia chromosome-<br class=br>negative relapsed or refractory B-cell<br class=br>precursor acute lymphoblastic leukemia<br class=br>(ALL)</td></tr><tr><a name=d89253e3184 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3186 class=n-a></a>4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3189 class=n-a></a>12/22/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3192 class=n-a></a>Nivolumab<br class=br>(Opdivo)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3197 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3200 class=n-a></a>Human anti-PD-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3204 class=n-a></a>Treatment of unresectable or metastatic<br class=br>melanoma and disease progression<br class=br>following ipilimumab and, if BRAF V600<br class=br>mutation positive, a BRAF inhibitor</td></tr><tr><a name=d89253e3214 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3216 class=n-a></a>5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3219 class=n-a></a>10/16/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3222 class=n-a></a>Idarucizumab<br class=br>(Praxbind)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3227 class=n-a></a>Fab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3230 class=n-a></a>Humanized anti-<br class=br>dabigatran</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3236 class=n-a></a>Treatment of patients treated with<br class=br>Pradaxa when reversal of the<br class=br>anticoagulant effects of dabigatran is<br class=br>needed for emergency surgery/urgent<br class=br>procedures and in life-threatening or<br class=br>uncontrolled bleeding</td></tr><tr><a name=d89253e3251 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3253 class=n-a></a>6</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3256 class=n-a></a>10/23/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3259 class=n-a></a>Asfotase-alfa<br class=br>(Strensiq)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3264 class=n-a></a>Enzyme/fusion<br class=br>protein</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3269 class=n-a></a>Tissue non-specific<br class=br>alkaline phosphatase/Fc<br class=br>fusion/deca-asparatate<br class=br>(D10) peptide</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3279 class=n-a></a>Treatment of patients with perinatal/<br class=br>infantile- and juvenile-onset<br class=br>hypophosphatasia</td></tr><tr><a name=d89253e3287 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3289 class=n-a></a>7</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3292 class=n-a></a>11/16/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3295 class=n-a></a>Daratumumab<br class=br>(Darzalex)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3300 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3303 class=n-a></a>Human anti-CD38</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3307 class=n-a></a>Treatment of patients with multiple<br class=br>myeloma who have received at least<br class=br>three prior lines of therapy, including<br class=br>a proteasome inhibitor and an<br class=br>immunomodulatory agent, or are double-<br class=br>refractory to a proteasome inhibitor and<br class=br>an immunomodulatory<br class=br>agent</td></tr><tr><a name=d89253e3326 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3328 class=n-a></a>8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3331 class=n-a></a>11/30/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3334 class=n-a></a>Elotuzumab<br class=br>(Empliciti)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3339 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3342 class=n-a></a>Humanized anti-<br class=br>CD319(SLAMF7)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3348 class=n-a></a>Treatment of patients with multiple<br class=br>myeloma who have received one to<br class=br>three prior therapies</td></tr><tr><a name=d89253e3356 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3358 class=n-a></a>9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3361 class=n-a></a>12/08/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3364 class=n-a></a>Sebelipase alfa<br class=br>(Kanuma)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3369 class=n-a></a>Enzyme</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3372 class=n-a></a>Lysosomal acid lipase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3376 class=n-a></a>Treatment of patients with a diagnosis of<br class=br>lysosomal acid lipase deficiency</td></tr><tr><a name=d89253e3382 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3384 class=n-a></a>10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3387 class=n-a></a>5/18/2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3390 class=n-a></a>Atezolizumab<br class=br>(Tecentriq)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3395 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3398 class=n-a></a>Humanized anti-PD-L1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3402 class=n-a></a>Treatment of locally advanced or<br class=br>metastatic urothelial carcinoma who<br class=br>have disease progression during<br class=br>or following platinum-containing<br class=br>chemotherapy or have disease<br class=br>progression within 12 months of<br class=br>neoadjuvant or adjuvant treatment with<br class=br>platinum-containing chemotherapy</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d89253e3425 class=n-a></a><p id=d89253e3427> Comprehensive listing of all FDA-approved therapeutic proteins granted breakthrough therapy designation upon original submission from July 9, 2012, through August 31, 2016, listed in chronological order of FDA approval. In addition, the class of protein, a brief description, and use are included. BRAF, B-Raf proto-oncogene, serine/threonine kinase; CD, cluster of differentiation; Fab, fragment antigen binding; mAb, monoclonal antibody; PD-1, programmed death receptor-1; PD-L1, programmed death-ligand 1; SLAMF7, SLAM family member 7.</p></div></div></div></div><div class=section><a name=d89253e3434 class=n-a></a><h3 class=section-title>Orphan designation</h3><p class="" id=d89253e3439>Rare diseases substantially impact public health, as an estimated 7,000 different disorders collectively affect approximately 10% of the U.S. population, young children particularly, and many lack effective treatments<sup><a href="#ref-24">24</a></sup>. To promote the development of medicines that specifically address unmet medical needs, an orphan designation is given for drugs indicated for the treatment of fewer than 200,000 patients in the U.S. On June 12, 2013, the final regulations amending the 1992 Orphan Drug Regulations were issued<sup><a href="#ref-25">25</a></sup>. These amendments clarified and instituted minor changes to regulatory language, such as defining the term “orphan subsets”, the eligibility of designation for previously approved drugs, and the scope of orphan exclusive approval (<a target=xrefwindow href="https://www.gpo.gov/fdsys/pkg/FR-2013-06-12/pdf/2013-13930.pdf" id=d89253e3449>https://www.gpo.gov/fdsys/pkg/FR-2013-06-12/pdf/2013-13930.pdf</a>). Under the Orphan Drug Act (ODA) Final Rule, orphan designation grants incentives such as orphan exclusivity for a specific indication (7-year protection from competition), thereby promoting innovation in drug development to help treat patients in greatest need of novel medicines. This program appears to have fulfilled a real need, as 50% of the recently approved therapeutic proteins (31 out of 62) were licensed under the orphan designation (<a href="#T5">Table 5</a>).</p><div class="table-wrap panel clearfix"><a name=T5 class=n-a></a><div class=caption><h3>Table 5. Therapeutic proteins granted orphan designation upon original submission (2011–2016).</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d89253e3467 class=n-a></a><thead><a name=d89253e3469 class=n-a></a><tr><a name=d89253e3471 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e3473 class=n-a></a>#</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e3476 class=n-a></a>Approval<br class=br>date</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e3481 class=n-a></a>Drug name<br class=br>(Market name)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e3486 class=n-a></a>Class</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e3489 class=n-a></a>Description</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e3493 class=n-a></a>Orphan designation</th></tr></thead><tbody><a name=d89253e3498 class=n-a></a><tr><a name=d89253e3500 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3502 class=n-a></a>1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3505 class=n-a></a>3/25/2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3508 class=n-a></a>Ipilimumab<br class=br>(Yervoy)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3513 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3516 class=n-a></a>Human anti-CTLA-4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3520 class=n-a></a>Treatment of high-risk stage II, stage III,<br class=br>and stage IV melanoma</td></tr><tr><a name=d89253e3526 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3528 class=n-a></a>2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3531 class=n-a></a>6/15/2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3534 class=n-a></a>Belatacept<br class=br>(Nulojix)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3539 class=n-a></a>Fusion (Fc)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3542 class=n-a></a>CTLA-4 Fc-fusion</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3546 class=n-a></a>Prophylaxis of organ rejection in renal<br class=br>allograft recipients</td></tr><tr><a name=d89253e3552 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3554 class=n-a></a>3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3557 class=n-a></a>11/18/2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3560 class=n-a></a>Asparaginase erwinia<br class=br>chrysanthemi<br class=br>(Erwinaze)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3567 class=n-a></a>Enzyme</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3570 class=n-a></a>Asparaginase erwinia<br class=br>chrysanthemi</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3576 class=n-a></a>Treatment of acute lymphocytic<br class=br>leukemia</td></tr><tr><a name=d89253e3582 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3584 class=n-a></a>4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3587 class=n-a></a>1/17/2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3590 class=n-a></a>Glucarpidase<br class=br>(Voraxaze)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3595 class=n-a></a>Enzyme</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3598 class=n-a></a>Glucarpidase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3602 class=n-a></a>Treatment of patients at risk of<br class=br>methotrexate toxicity</td></tr><tr><a name=d89253e3608 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3610 class=n-a></a>5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3613 class=n-a></a>5/1/2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3616 class=n-a></a>Taliglucerase alfa<br class=br>(Elelyso)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3621 class=n-a></a>Enzyme</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3624 class=n-a></a>Taliglucerase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3628 class=n-a></a>Treatment of Gaucher’s disease</td></tr><tr><a name=d89253e3633 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3635 class=n-a></a>6</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3638 class=n-a></a>12/14/2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3641 class=n-a></a>Raxibacumab<br class=br>(raxibacumab)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3646 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3649 class=n-a></a>Human anti-anthrax<br class=br>protective antigen (PA)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3655 class=n-a></a>Treatment of anthrax</td></tr><tr><a name=d89253e3659 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3661 class=n-a></a>7</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3664 class=n-a></a>6/26/2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3667 class=n-a></a>Coagulation factor IX<br class=br>recombinant human<br class=br>(Rixubis)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3674 class=n-a></a>Coagulation factor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3677 class=n-a></a>Recombinant factor IX</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3681 class=n-a></a>Prophylactic use to prevent or reduce<br class=br>the frequency of bleeding episodes<br class=br>in patients with hemophilia B (routine<br class=br>prophylaxis in patients where there is<br class=br>no evidence or suspicion of bleeding)</td></tr><tr><a name=d89253e3693 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3695 class=n-a></a>8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3698 class=n-a></a>11/1/2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3701 class=n-a></a>Obinutuzumab<br class=br>(Gazyva)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3706 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3709 class=n-a></a>Humanized anti-CD20</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3713 class=n-a></a>Treatment of chronic lymphocytic<br class=br>leukemia</td></tr><tr><a name=d89253e3719 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3721 class=n-a></a>9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3724 class=n-a></a>12/23/2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3727 class=n-a></a>Coagulation factor<br class=br>XIII A-subunit<br class=br>(recombinant)<br class=br>(Tretten)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3736 class=n-a></a>Coagulation factor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3739 class=n-a></a>Recombinant factor XIII<br class=br>A subunit</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3745 class=n-a></a>Prophylaxis of bleeding associated with<br class=br>congential factor XIII deficiency</td></tr><tr><a name=d89253e3751 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3753 class=n-a></a>10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3756 class=n-a></a>2/14/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3759 class=n-a></a>Elosulfase alfa<br class=br>(Vimizim)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3764 class=n-a></a>Enzyme</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3767 class=n-a></a>Elosulfase alfa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3771 class=n-a></a>Treatment of mucopolysaccharidosis<br class=br>type IV A (Morquio A syndrome)</td></tr><tr><a name=d89253e3777 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3779 class=n-a></a>11</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3782 class=n-a></a>2/24/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3785 class=n-a></a>Metreleptin<br class=br>(Myalept)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3790 class=n-a></a>Hormone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3793 class=n-a></a>Metreleptin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3797 class=n-a></a>Treatment of metabolic disorders<br class=br>secondary to lipodystrophy</td></tr><tr><a name=d89253e3804 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3806 class=n-a></a>12</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3809 class=n-a></a>3/28/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3812 class=n-a></a>Coagulation factor IX<br class=br>(recombinant),<br class=br>Fc fusion protein<br class=br>(Alprolix)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3821 class=n-a></a>Coagulation factor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3824 class=n-a></a>Recombinant factor IX<br class=br>Fc fusion</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3830 class=n-a></a>Control and prevention of hemorrhagic<br class=br>episodes in patients with hemophilia<br class=br>B (congenital factor IX deficiency or<br class=br>Christmas disease)</td></tr><tr><a name=d89253e3840 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3842 class=n-a></a>13</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3845 class=n-a></a>4/21/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3848 class=n-a></a>Ramucirumab<br class=br>(Cyramza)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3853 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3856 class=n-a></a>Human anti-VEGFR2<br class=br>(KDR)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3862 class=n-a></a>Treatment of gastric cancer</td></tr><tr><a name=d89253e3866 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3868 class=n-a></a>14</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3871 class=n-a></a>4/23/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3874 class=n-a></a>Siltuximab (Sylvant)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3877 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3880 class=n-a></a>Mouse/human chimeric<br class=br>anti-IL-6</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3886 class=n-a></a>Treatment of Castleman’s disease</td></tr><tr><a name=d89253e3890 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3892 class=n-a></a>15</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3895 class=n-a></a>4/23/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3898 class=n-a></a>Pembrolizumab<br class=br>(Keytruda)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3903 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3906 class=n-a></a>Humanized anti-PD-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3910 class=n-a></a>Treatment of stage IIB through IV<br class=br>malignant melanoma</td></tr><tr><a name=d89253e3916 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3918 class=n-a></a>16</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3921 class=n-a></a>6/6/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3924 class=n-a></a>Antihemophilic<br class=br>factor (recombinant),<br class=br>Fc fusion protein<br class=br>(Eloctate)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3933 class=n-a></a>Coagulation factor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3936 class=n-a></a>Recombinant factor VIII<br class=br>Fc-fusion</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3942 class=n-a></a>Treatment of hemophilia A</td></tr><tr><a name=d89253e3946 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3948 class=n-a></a>17</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3951 class=n-a></a>7/16/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3954 class=n-a></a>C1 esterase inhibitor<br class=br>recombinant<br class=br>(Ruconest)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3961 class=n-a></a>Plasma protein</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3964 class=n-a></a>Recombinant C1<br class=br>esterase inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3970 class=n-a></a>Treatment of (acute attacks of)<br class=br>angioedema caused by hereditary<br class=br>or acquired C1-esterase inhibitor<br class=br>deficiency</td></tr><tr><a name=d89253e3981 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3983 class=n-a></a>18</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3986 class=n-a></a>10/23/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e3989 class=n-a></a>Antihemophilic factor<br class=br>porcine,<br class=br>B-domain truncated<br class=br>recombinant<br class=br>(Obizur)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4000 class=n-a></a>Coagulation factor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4003 class=n-a></a>Recombinant factor VIII<br class=br>(porcine)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4009 class=n-a></a>Treatment and prevention of episodic<br class=br>bleeding in patients with inhibitor<br class=br>antibodies to human coagulation<br class=br>factor VIII</td></tr><tr><a name=d89253e4019 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4021 class=n-a></a>19</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4024 class=n-a></a>12/3/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4027 class=n-a></a>Blinatumomab<br class=br>(Blincyto)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4032 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4035 class=n-a></a>Mouse bispecific anti-<br class=br>CD19/anti-CD3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4041 class=n-a></a>Treatment of acute lymphocytic<br class=br>leukemia</td></tr><tr><a name=d89253e4047 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4049 class=n-a></a>20</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4052 class=n-a></a>12/22/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4055 class=n-a></a>Nivolumab<br class=br>(Opdivo)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4060 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4063 class=n-a></a>Human anti-PD-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4067 class=n-a></a>Treatment of stage IIb to IV melanoma</td></tr><tr><a name=d89253e4071 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4073 class=n-a></a>21</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4076 class=n-a></a>1/23/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4079 class=n-a></a>Parathyroid hormone<br class=br>(Natpara)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4084 class=n-a></a>Hormone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4087 class=n-a></a>Parathyroid hormone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4091 class=n-a></a>Treatment of hypoparathyroidism</td></tr><tr><a name=d89253e4095 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4097 class=n-a></a>22</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4100 class=n-a></a>3/10/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4103 class=n-a></a>Dinutuximab<br class=br>(Unituxin)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4108 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4111 class=n-a></a>Mouse/human chimeric<br class=br>anti-GD2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4117 class=n-a></a>Treatment of neuroblastoma</td></tr><tr><a name=d89253e4121 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4123 class=n-a></a>23</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4126 class=n-a></a>8/27/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4129 class=n-a></a>Evolocumab<br class=br>(Repatha)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4134 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4137 class=n-a></a>Human anti-proprotein<br class=br>convertase substilisin/<br class=br>kexin type 9 (PCSK9)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4145 class=n-a></a>Treatment of homozygous familial<br class=br>hypercholesterolemia</td></tr><tr><a name=d89253e4152 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4154 class=n-a></a>24</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4157 class=n-a></a>10/16/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4160 class=n-a></a>Idarucizumab<br class=br>(Praxbind)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4165 class=n-a></a>Fab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4168 class=n-a></a>Humanized anti-<br class=br>dabigatran</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4174 class=n-a></a>To reverse the anticoagulant effect of<br class=br>dabigatran due to uncontrolled life-<br class=br>threatening bleeding requiring urgent<br class=br>intervention or a need to undergo an<br class=br>emergency surgery/urgent invasive<br class=br>procedure</td></tr><tr><a name=d89253e4188 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4190 class=n-a></a>25</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4193 class=n-a></a>10/23/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4196 class=n-a></a>Asfotase-alfa<br class=br>(Strensiq)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4201 class=n-a></a>Enzyme/fusion<br class=br>protein</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4206 class=n-a></a>Tissue non-specific<br class=br>alkaline phosphatase/<br class=br>Fc fusion/deca-<br class=br>asparatate (D10)<br class=br>peptide</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4218 class=n-a></a>Treatment of hypophosphatasia</td></tr><tr><a name=d89253e4222 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4224 class=n-a></a>26</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4227 class=n-a></a>11/16/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4230 class=n-a></a>Daratumumab<br class=br>(Darzalex)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4235 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4238 class=n-a></a>Human anti-CD38</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4242 class=n-a></a>Treatment of multiple myeloma</td></tr><tr><a name=d89253e4246 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4248 class=n-a></a>27</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4251 class=n-a></a>11/24/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4254 class=n-a></a>Necitumumab<br class=br>(Portrazza)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4259 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4262 class=n-a></a>Human anti-epidermal<br class=br>growth factor receptor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4268 class=n-a></a>Treatment of squamous non-small cell<br class=br>lung cancer</td></tr><tr><a name=d89253e4274 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4276 class=n-a></a>28</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4279 class=n-a></a>12/8/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4282 class=n-a></a>Sebelipase alfa<br class=br>(Kanuma)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4287 class=n-a></a>Enzyme</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4290 class=n-a></a>Lysosomal acid lipase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4294 class=n-a></a>Treatment of lysosomal acid lipase<br class=br>deficiency</td></tr><tr><a name=d89253e4300 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4302 class=n-a></a>29</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4305 class=n-a></a>12/8/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4308 class=n-a></a>von Willebrand Factor<br class=br>(Recombinant)<br class=br>(Vonvendi)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4315 class=n-a></a>Plasma protein</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4318 class=n-a></a>Recombinant von<br class=br>Willebrand Factor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4324 class=n-a></a>Treatment of von Willebrand disease</td></tr><tr><a name=d89253e4329 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4331 class=n-a></a>30</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4334 class=n-a></a>3/4/2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4337 class=n-a></a>Coagulation factor IX<br class=br>recombinant human<br class=br>(Idelvion)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4344 class=n-a></a>Coagulation factor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4347 class=n-a></a>Recombinant factor IX<br class=br>albumin fusion</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4353 class=n-a></a>Treatment of patients with congenital<br class=br>factor IX deficiency (hemophilia B)</td></tr><tr><a name=d89253e4359 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4361 class=n-a></a>31</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4364 class=n-a></a>3/18/2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4367 class=n-a></a>Obiltoxaximab<br class=br>(Anthim)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4372 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4375 class=n-a></a>Mouse/human chimeric<br class=br>anti-<i>Bacillus anthracis</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4384 class=n-a></a>Treatment of exposure to <i>B. anthracis</i><br class=br>spores</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d89253e4396 class=n-a></a><p id=d89253e4398> Comprehensive listing of all FDA-approved therapeutic proteins granted orphan designation upon original submission from January 1, 2011, through August 31, 2016, listed in chronological order of FDA approval. In addition, the class of protein, a brief description, and orphan designation are included. CD, cluster of differentiation; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; Fab, fragment antigen binding; Fc, fragment crystallizable; GD2, disialoganglioside; IL, interleukin; mAb, monoclonal antibody; PD-1, programmed death receptor-1; VEGFR, vascular endothelial growth factor receptor.</p></div></div></div></div><div class=section><a name=d89253e4406 class=n-a></a><h3 class=section-title>Biosimilars</h3><p class="" id=d89253e4411>Therapeutic protein drugs are now a critical component of the overall health-care industry and have revolutionized therapy options in many disease areas. These medications, however, are also some of the most expensive in the marketplace. It had become imperative to extend the generic concept for the licensure of therapeutic protein drugs because, while there existed only a few biopharmaceuticals when the Drug Price Competition and Patent Term Restoration Act of 1984 (Waxman-Hatch Act) was passed, these now account for almost a third of pharmaceutical sales, represent a core component of modern pharmacotherapy, and include the most expensive drugs on the market<sup><a href="#ref-26">26</a></sup>. As many biopharmaceuticals are poised to go off-patent, it has been recognized in both the U.S. and Europe that replicating the highly successful model of generic drugs to contain the costs of these therapeutics is a desirable goal, because biosimilar biological products (biosimilars) could potentially reduce the costs of therapeutic protein drugs.</p><p class="" id=d89253e4418>In 2010, as part of the Patient Protection and Affordable Care Act (Affordable Care Act), biologics deemed to be “biosimilar” to an existing FDA-approved reference product were granted an abbreviated drug review and licensure pathway. Over the last few years, the FDA has issued several guidances to help sponsors navigate this novel regulatory pathway<sup><a href="#ref-27">27</a>–<a href="#ref-30">30</a></sup>. As of August 31, 2016, three biosimilars have been approved by the FDA (Purple Book<sup><a href="#ref-22">22</a></sup>). The first FDA-approved biosimilar, filgrastim-sndz (Zarxio; Sandoz), a biosimilar of filgrastim (Neupogen; Amgen), was approved on March 6, 2015, as a leukocyte growth factor for use in several neutropenia-related indications<sup><a href="#ref-31">31</a></sup>. This landmark approval was followed by the approval of infliximab-dyyb (Inflectra; Celltrion), a biosimilar of infliximab (Remicade; Janssen), on April 5, 2016<sup><a href="#ref-32">32</a></sup>, and the approval of etanercept-szzs (Erelzi; Sandoz), a biosimilar of etanercept (Enbrel; Amgen), on August 30, 2016<sup><a href="#ref-33">33</a></sup>; both are tumor necrosis factor (TNF) blockers indicated for use in inflammatory conditions. With the upcoming patent cliff approaching for several “blockbuster” therapeutic protein drugs, there is the expectation that the number of approved biosimilars will increase over the coming years. This trend has already been observed in Europe, where 21 biosimilar medicines have been authorized by the European Medicines Agency since 2006.</p><p class="" id=d89253e4444>Although a drug product is off-patent, competitors do not get direct access to the originator company’s proprietary data or to resources such as the DNA sequence or cell lines used during the manufacture. Typically, the developer of a biosimilar has to retrieve the reference protein as a finished drug product, purify the drug substance, and reverse-engineer the process. Consequently, the FDA biosimilar framework does not require an identical manufacturing process for the innovator product and the biosimilar. Therefore, it is not expected that, in the demonstration of biosimilarity, quality attributes such as protein structure and post-translational modifications measured in comparative physiochemical and functional studies will be identical between the biosimilar and reference product, but highly similar. It has, on the contrary, been argued that deviations from the technology of the innovator may actually be desirable<sup><a href="#ref-9">9</a>,<a href="#ref-34">34</a></sup>. This is because since the introduction of the first recombinant DNA-derived therapeutic proteins, the technology to produce and purify these products has greatly improved. An increased focus upon innovation and streamlining of upstream and downstream processing has been reported by the widely respected “Biopharmaceutical benchmarks” series<sup><a href="#ref-3">3</a>,<a href="#ref-35">35</a></sup>. Thus, it is not necessary for manufacturers of biosimilars to be locked into the obsolete technologies of the manufacturers of the original products for whom changing methods have major financial and regulatory consequences. With this in mind, it seems much more desirable for biosimilars to be produced and analyzed by the best technology on offer.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d89253e4465>Emerging trends, challenges, and opportunities</h2><p class="" id=d89253e4468>As protein-engineering technologies and regulatory frameworks evolve over time, so do protein therapeutics. Optimized versions of existing therapies can be achieved through better drug targeting as well as enhancing potency and functionality. By understanding the mechanism of action as well as the structure-function relationship of a protein, rational design and engineering strategies allow the modification of its activity or the introduction of new activities, leading to customization of existing proteins or the generation of novel therapeutics for specific clinical applications. Here, we will highlight just two examples of rational modifications to existing protein drugs achieved through protein engineering that have led to the approval of novel second-generation therapeutics (see <a href="#B1">Box 1</a> and <a href="#B2">Box 2</a>).</p><div class="boxed-text panel clearfix"><a name=B1 class=n-a></a><div class=caption><h3>Box 1. Engineering a second-generation cytotoxic T lymphocyte-associated protein 4 (CTLA4)-Fc fusion</h3></div><p class="" id=d89253e4488>Abatacept, a CTLA4-Fc fusion protein therapeutic, was developed by Bristol-Myers Squibb and approved by the U.S. Food and Drug Administration (FDA) in December 2005 as the first selective modulator of co-stimulation for the treatment of rheumatoid arthritis<sup><a href="#ref-62">62</a></sup>. CTLA4-Fc competitively inhibits CD28 on the surface of T cells for binding to the B7 family co-stimulatory receptors CD80 (B7-1) and CD86 (B7-2) expressed on the surface of antigen-presenting cells. Although this Fc-fusion has been shown to be efficacious in the treatment of rheumatoid arthritis, abatacept was not as effective when tested pre-clinically in non-human primate transplant models<sup><a href="#ref-63">63</a>,<a href="#ref-64">64</a></sup>. Experimental data suggested that abatacept did not completely block B7 co-stimulatory receptor-mediated T-cell activation; therefore, a similar molecule with enhanced affinity for CD80/CD86 could be of therapeutic benefit as an immunosuppressant to prevent organ transplant rejection. Belatacept, formerly known as LEA29Y, was therefore developed by Bristol-Myers Squibb as a second-generation CTLA4-Fc. Two amino acid substitutions in the CTLA-4 ligand-binding region (L104E and A29Y) resulted in enhanced <i>in vitro</i> binding to CD80 (about two fold more avidly) and CD86 (about four fold more avidly) in addition to greater immunosuppression of T-cell activation <i>in vitro</i> (about 10-fold) as compared with the parent molecule (abatacept)<sup><a href="#ref-65">65</a></sup>. Belatacept’s enhanced activity was also observed <i>in vivo</i> with prolonged renal allograft survival in non-human primates (rhesus monkeys) compared with abatacept<sup><a href="#ref-63">63</a>,<a href="#ref-65">65</a></sup>. In clinical studies of kidney allograft recipients, belatacept was shown to be associated with similar levels of patient and graft survival but superior renal function and reduced renal and non-renal toxicities compared with cyclosporine at 12 months after transplant<sup><a href="#ref-66">66</a></sup>. The rationally designed analog with enhanced CD80 and CD86 binding, belatacept, a second-generation selective co-stimulation blocker, was approved by the FDA on June 15, 2011, for the prophylaxis of kidney transplant rejection<sup><a href="#ref-67">67</a></sup>.</p></div><div class="boxed-text panel clearfix"><a name=B2 class=n-a></a><div class=caption><h3>Box 2. Engineering a second-generation anti-CD20 monoclonal antibody (mAb)</h3></div><p class="" id=d89253e4543>Rituximab, a chimeric mouse/human type I anti-CD20 mAb, was developed by Genentech and approved by the U.S. Food and Drug Administration (FDA) in November 1997 for the treatment of B-cell non-Hodgkin’s lymphoma. Rituximab binds to CD20 expressed on the surface of many B cells (but not plasma cells), resulting in B-cell depletion via antibody-dependent cellular cytotoxicity (ADCC), complement-mediated cytotoxicity (CMA), and the induction of direct cell death (apoptosis)<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup>. Both ADCC and CMA are dependent upon the Fc region of the mAb interacting with Fc gamma receptor IIIA (FcγRIIIA) or complement component 1q (C1q), respectively. In the case of ADCC, antibody-bound CD20<sup>+</sup> B cells are targeted for cellular depletion by FcγRIIIA-expressing monocytes, macrophages, and natural killer cells. Given the importance of FcγRIIIA engagement and signaling in the mechanism of B-cell depletion, specifically engineering a next-generation mAb<sup><a href="#ref-70">70</a>–<a href="#ref-72">72</a></sup> with enhanced functional activity would be of clinical benefit. Gazyva, formerly known as GA101, a type II anti-CD20 mAb, was engineered and developed by Genentech. This second-generation medicine contains a CD20-binding variable region introduced through protein engineering to take advantage of the potent induction of direct cell death and limited C1q binding typical of type II anti-CD20 antibodies<sup><a href="#ref-51">51</a></sup>. The Fc region of this mAb has also been glyco-engineered by producing the protein drug in an expression cell line that overexpresses the glycosylation enzymes β1,4-<i>N</i>-acetylglucosaminyltransferase III (GnTIII) and Golgi α-mannosidase II (ManII)<sup><a href="#ref-73">73</a></sup>, thereby enriching for afucosylated oligosaccharides. Changes to the Fc glycosylation at Asn297 can lead to changes in FcγR binding, phagocytosis, and cytotoxicity<sup><a href="#ref-74">74</a></sup>. In fact, afucosylated antibodies have higher-affinity FcγRIIIA binding and enhanced ADCC activity compared with parent fucosylated counterparts<sup><a href="#ref-20">20</a>,<a href="#ref-75">75</a></sup>. The effects of these protein-engineering strategies can be observed in pre-clinical studies as Gazyva demonstrated higher affinity to FcγRIIIA by SPR and induced more potent ADCC when compared with rituximab<sup><a href="#ref-51">51</a></sup>. These significant improvements were also observed in phase 3 clinical studies as patients with CD20<sup>+</sup> chronic lymphocytic leukemia treated with Gazyva with chlorambucil had prolonged median progression-free survival time (26.7 months) when compared with patients treated with rituximab with chlorambucil (15.2 months)<sup><a href="#ref-76">76</a></sup>. On November 1, 2013, Gazyva became the first glyco-engineered mAb drug to be approved by the FDA. This second-generation anti-CD20 mAb for treatment of chronic lymphocytic leukemia was also the first therapeutic protein to receive breakthrough therapy designation. In addition, Gazyva was granted orphan designation upon approval and contains pharmacogenetics information included on the drug label.</p></div><p class="" id=d89253e4598>Over this examination of the recently approved therapeutic protein drug landscape, several emerging trends have become apparent. We anticipate that the inclusion of pharmacogenetics information in drug labeling and the importance of “companion diagnostics” will become the focus of increased attention. The FDA has been encouraging drug developers to collect and submit pharmacogenomics data through a guidance, “Pharmacogenomic Data Submissions”, issued in March 2005<sup><a href="#ref-36">36</a></sup>. Pharmacogenetics can play an important role in identifying responders and non-responders to medications, avoiding adverse events, and optimizing drug dose. Drug labeling may contain information on genomic biomarkers and can describe drug exposure and clinical response variability, risk for adverse events, genotype-specific dosing, mechanisms of drug action, and polymorphic drug target and disposition genes. Therefore, pharmacogenetic profiling is of particular importance when potential drug candidates exhibit highly variable safety, efficacy, or pharmacokinetics profiles. In January 2013, the FDA issued a guidance, titled “Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling”, to assist drug developers with conducting exploratory pharmacogenomic investigations, enrichment strategies for clinical trials, adaptive trial designs, or companion diagnostics<sup><a href="#ref-37">37</a></sup>. Pharmacogenetic information and changes in drug labeling can lead to drugs targeted for different populations, personalized dosing regimens, and companion diagnostics. There have been 11 therapeutic proteins approved since 2011 that have included pharmacogenetic biomarkers in their drug labels (<a href="#T6">Table 6</a>). For a complete listing of drugs with available pharmacogenetics information, see the FDA’s Table of Pharmacogenomic Biomarkers in Drug Labeling<sup><a href="#ref-38">38</a></sup>. The FDA’s review process will continue to adapt as the incorporation of pharmacogenetic information becomes more commonplace. This will also require a coordinated cross-center review to incorporate the companion diagnostic/sequencing in the drug development/licensure process.</p><div class="table-wrap panel clearfix"><a name=T6 class=n-a></a><div class=caption><h3>Table 6. Therapeutic proteins with pharmacogenetic biomarkers in drug labeling.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d89253e4628 class=n-a></a><thead><a name=d89253e4630 class=n-a></a><tr><a name=d89253e4632 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e4634 class=n-a></a>#</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e4637 class=n-a></a>Approval<br class=br>date</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e4642 class=n-a></a>Drug name<br class=br>(Market name)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e4647 class=n-a></a>Class</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e4650 class=n-a></a>Description</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e4654 class=n-a></a>Pharmacogenetic<br class=br>biomarker</th><th align=left colspan=1 rowspan=1 valign=top><a name=d89253e4659 class=n-a></a>Therapeutic area</th></tr></thead><tbody><a name=d89253e4664 class=n-a></a><tr><a name=d89253e4666 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4668 class=n-a></a>1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4671 class=n-a></a>6/8/2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4674 class=n-a></a>Pertuzumab<br class=br>(Perjeta)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4679 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4682 class=n-a></a>Humanized anti-<br class=br>human epidermal<br class=br>growth factor receptor 2 (HER2)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4690 class=n-a></a>HER2 protein<br class=br>overexpression positive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4695 class=n-a></a>Oncology</td></tr><tr><a name=d89253e4699 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4701 class=n-a></a>2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4704 class=n-a></a>2/22/2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4707 class=n-a></a>Ado-trastuzumab<br class=br>emtansine<br class=br>(Kadcyla)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4714 class=n-a></a>Antibody-<br class=br>drug conjugate</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4719 class=n-a></a>Humanized<br class=br>anti-HER2/neu<br class=br>conjugated to<br class=br>emtansine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4729 class=n-a></a>HER2 protein<br class=br>overexpression or gene<br class=br>amplification positive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4736 class=n-a></a>Oncology</td></tr><tr><a name=d89253e4740 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4742 class=n-a></a>3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4745 class=n-a></a>11/1/2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4748 class=n-a></a>Obinutuzumab<br class=br>(Gazyva)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4753 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4756 class=n-a></a>Humanized<br class=br>anti-CD20</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4762 class=n-a></a>CD20 antigen positive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4765 class=n-a></a>Oncology</td></tr><tr><a name=d89253e4769 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4771 class=n-a></a>4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4774 class=n-a></a>2/14/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4777 class=n-a></a>Elosulfase alfa<br class=br>(Vimizim)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4782 class=n-a></a>Enzyme</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4785 class=n-a></a>Elosulfase alfa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4789 class=n-a></a>N-acetylgalactosamine-6-<br class=br>sulfatase deficient</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4794 class=n-a></a>Inborn errors of<br class=br>metabolism</td></tr><tr><a name=d89253e4800 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4802 class=n-a></a>5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4805 class=n-a></a>9/4/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4808 class=n-a></a>Pembrolizumab<br class=br>(Keytruda)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4813 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4816 class=n-a></a>Humanized anti-PD-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4820 class=n-a></a>(1) BRAF V600 mutation<br class=br>positive, (2) PD-L1 protein<br class=br>expression positive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4827 class=n-a></a>Oncology</td></tr><tr><a name=d89253e4832 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4834 class=n-a></a>6</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4837 class=n-a></a>12/3/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4840 class=n-a></a>Blinatumomab<br class=br>(Blincyto)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4845 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4848 class=n-a></a>Mouse bispecific<br class=br>anti-CD19/anti-CD3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4854 class=n-a></a>Philadelphia chromosome<br class=br>negative</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4859 class=n-a></a>Oncology</td></tr><tr><a name=d89253e4863 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4865 class=n-a></a>7</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4868 class=n-a></a>12/22/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4871 class=n-a></a>Nivolumab<br class=br>(Opdivo)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4876 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4879 class=n-a></a>Human anti-PD-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4883 class=n-a></a>(1) BRAF V600 mutation<br class=br>positive, (2) PD-L1 protein<br class=br>expression positive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4890 class=n-a></a>Oncology</td></tr><tr><a name=d89253e4894 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4896 class=n-a></a>8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4899 class=n-a></a>1/23/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4902 class=n-a></a>Parathyroid<br class=br>hormone<br class=br>(Natpara)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4909 class=n-a></a>Hormone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4912 class=n-a></a>Parathyroid hormone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4916 class=n-a></a>Calcium sensing receptor<br class=br>mutation positive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4921 class=n-a></a>Inborn errors of<br class=br>metabolism</td></tr><tr><a name=d89253e4927 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4929 class=n-a></a>9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4932 class=n-a></a>3/10/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4935 class=n-a></a>Dinutuximab<br class=br>(Unituxin)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4940 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4943 class=n-a></a>Mouse/human<br class=br>chimeric anti-GD2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4949 class=n-a></a>MYCN amplification positive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4952 class=n-a></a>Oncology</td></tr><tr><a name=d89253e4956 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4958 class=n-a></a>10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4961 class=n-a></a>7/24/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4964 class=n-a></a>Alirocumab<br class=br>(Praluent)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4969 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4972 class=n-a></a>Human anti-<br class=br>proprotein<br class=br>convertase<br class=br>substilisin/kexin<br class=br>type 9 (PCSK9)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4984 class=n-a></a>LDL receptor mutation<br class=br>heterozygotes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4989 class=n-a></a>Endocrinology</td></tr><tr><a name=d89253e4993 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4995 class=n-a></a>11</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e4998 class=n-a></a>8/27/2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e5001 class=n-a></a>Evolocumab<br class=br>(Repatha)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e5006 class=n-a></a>mAb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e5009 class=n-a></a>Human anti-<br class=br>proprotein<br class=br>convertase<br class=br>substilisin/kexin<br class=br>type 9 (PCSK9)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e5021 class=n-a></a>LDL receptor mutation<br class=br>heterozygotes and<br class=br>homozygotes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d89253e5028 class=n-a></a>Endocrinology</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d89253e5036 class=n-a></a><p id=d89253e5038> Comprehensive listing of all FDA-approved therapeutic proteins with pharmacogenetics biomarkers in drug labeling from January 1, 2011, through August 31, 2016, listed in chronological order of FDA approval. In addition, the class of protein, a brief description, pharmacogenetics biomarker, and therapeutic area are included. BRAF, B-Raf proto-oncogene, serine/threonine kinase; CD, cluster of differentiation; GD2, disialoganglioside; LDL, low-density lipoprotein; mAb, monoclonal antibody; MYCN, v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog; PD-1, programmed death receptor-1; PD-L1, programmed death-ligand 1.</p></div></div></div><p class="" id=d89253e5044>It is reasonable to anticipate that proteins will be more extensively engineered in the future. This means that the new generation of therapeutic proteins will carry neo-sequences not found in nature. Thus, the potential risks of immunogenicity (undesirable immune responses to therapeutic proteins)<sup><a href="#ref-39">39</a></sup> will also increase and, in turn, demand new technologies for immunogenicity risk assessment and mitigation<sup><a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup>. Protein engineering is no longer restricted to altering the primary sequence of proteins. On the other hand, the rapidly growing trend of codon optimization involves the substitution of synonymous codons to improve protein synthesis and increase protein production<sup><a href="#ref-41">41</a>,<a href="#ref-42">42</a></sup>. A growing scientific literature suggests that although synonymous codons do not alter protein sequence they can have profound effects on protein folding and function<sup><a href="#ref-43">43</a>–<a href="#ref-45">45</a></sup>. Consequently, these therapeutic proteins designed by using such strategies will have to be carefully evaluated.</p><p class="" id=d89253e5072>Finally, a confluence of computational and high-throughput experimental methods for protein-engineering and “off the shelf” platform technologies has ushered in unprecedented opportunities to develop safe, effective, and more convenient protein therapeutics. These opportunities do come with risks but rapid advances in new technologies as well as the underlying science suggest that these risks can be managed.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d89253e1 class=n-a></a><h2 class=main-title id=d89470>Competing interests</h2><p class=metadata-entry><a name=d89253e163 class=n-a></a><p id=d89253e165> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d89253e1 class=n-a></a><h2 class=main-title id=d89472>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d89253e5079 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d89698>References</h2><div class="section ref-list"><a name=d89253e5079 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d89253e5086 class=n-a></a>Kimchi-Sarfaty C, Schiller T, Hamasaki-Katagiri N, <i> et al.</i>: Building better drugs: developing and regulating engineered therapeutic proteins. <i>Trends Pharmacol Sci.</i> 2013; <b>34</b>(10): 534–48. <a target=xrefwindow id=d89253e5097 href="http://www.ncbi.nlm.nih.gov/pubmed/24060103">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5100 href="http://dx.doi.org/10.1016/j.tips.2013.08.005">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d89253e5109 class=n-a></a>Carter PJ: Introduction to current and future protein therapeutics: a protein engineering perspective. <i>Exp Cell Res.</i> 2011; <b>317</b>(9): 1261–9. <a target=xrefwindow id=d89253e5117 href="http://www.ncbi.nlm.nih.gov/pubmed/21371474">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5120 href="http://dx.doi.org/10.1016/j.yexcr.2011.02.013">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d89253e5129 class=n-a></a>Walsh G: Biopharmaceutical benchmarks 2014. <i>Nat Biotechnol.</i> 2014; <b>32</b>(10): 992–1000. <a target=xrefwindow id=d89253e5137 href="http://www.ncbi.nlm.nih.gov/pubmed/25299917">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5140 href="http://dx.doi.org/10.1038/nbt.3040">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d89253e5149 class=n-a></a>Schellekens H: Biosimilar therapeutics-what do we need to consider? <i>NDT Plus.</i> 2009; <b>2</b>(Suppl_1): i27–i36. <a target=xrefwindow id=d89253e5157 href="http://www.ncbi.nlm.nih.gov/pubmed/19461855">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5160 href="http://dx.doi.org/10.1093/ndtplus/sfn177">Publisher Full Text </a> | <a target=xrefwindow id=d89253e5163 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2638545">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d89253e5172 class=n-a></a>Bandaranayake AD, Almo SC: Recent advances in mammalian protein production. <i>FEBS Lett.</i> 2014; <b>588</b>(2): 253–60. <a target=xrefwindow id=d89253e5180 href="http://www.ncbi.nlm.nih.gov/pubmed/24316512">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5183 href="http://dx.doi.org/10.1016/j.febslet.2013.11.035">Publisher Full Text </a> | <a target=xrefwindow id=d89253e5186 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3924552">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d89253e5196 class=n-a></a>Butler M, Meneses-Acosta A: Recent advances in technology supporting biopharmaceutical production from mammalian cells. <i>Appl Microbiol Biotechnol.</i> 2012; <b>96</b>(4): 885–94. <a target=xrefwindow id=d89253e5204 href="http://www.ncbi.nlm.nih.gov/pubmed/23053101">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5207 href="http://dx.doi.org/10.1007/s00253-012-4451-z">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d89253e5216 class=n-a></a>Zhu J: Mammalian cell protein expression for biopharmaceutical production. <i>Biotechnol Adv.</i> 2012; <b>30</b>(5): 1158–70. <a target=xrefwindow id=d89253e5224 href="http://www.ncbi.nlm.nih.gov/pubmed/21968146">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5227 href="http://dx.doi.org/10.1016/j.biotechadv.2011.08.022">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718783021"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d89253e5236 class=n-a></a>Cipriano D, Burnham M, Hughes JV: Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps. <i>Methods Mol Biol.</i> 2012; <b>899</b>: 277–92. <a target=xrefwindow id=d89253e5244 href="http://www.ncbi.nlm.nih.gov/pubmed/22735960">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5247 href="http://dx.doi.org/10.1007/978-1-61779-921-1_18">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718783021">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d89253e5260 class=n-a></a>Chirino AJ, Mire-Sluis A: Characterizing biological products and assessing comparability following manufacturing changes. <i>Nat Biotechnol.</i> 2004; <b>22</b>(11): 1383–91. <a target=xrefwindow id=d89253e5268 href="http://www.ncbi.nlm.nih.gov/pubmed/15529163">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5271 href="http://dx.doi.org/10.1038/nbt1030">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d89253e5280 class=n-a></a>Tobin PH, Richards DH, Callender RA, <i> et al.</i>: Protein engineering: a new frontier for biological therapeutics. <i>Curr Drug Metab.</i> 2014; <b>15</b>(7): 743–56. <a target=xrefwindow id=d89253e5291 href="http://www.ncbi.nlm.nih.gov/pubmed/25495737">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5294 href="http://dx.doi.org/10.2174/1389200216666141208151524">Publisher Full Text </a> | <a target=xrefwindow id=d89253e5298 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4931902">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d89253e5307 class=n-a></a>Wurm FM: Production of recombinant protein therapeutics in cultivated mammalian cells. <i>Nat Biotechnol.</i> 2004; <b>22</b>(11): 1393–8. <a target=xrefwindow id=d89253e5315 href="http://www.ncbi.nlm.nih.gov/pubmed/15529164">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5318 href="http://dx.doi.org/10.1038/nbt1026">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d89253e5328 class=n-a></a>Lutz S: Beyond directed evolution--semi-rational protein engineering and design. <i>Curr Opin Biotechnol.</i> 2010; <b>21</b>(6): 734–43. <a target=xrefwindow id=d89253e5336 href="http://www.ncbi.nlm.nih.gov/pubmed/20869867">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5339 href="http://dx.doi.org/10.1016/j.copbio.2010.08.011">Publisher Full Text </a> | <a target=xrefwindow id=d89253e5342 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2982887">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d89253e5351 class=n-a></a>Levin D, Golding B, Strome SE, <i> et al.</i>: Fc fusion as a platform technology: potential for modulating immunogenicity. <i>Trends Biotechnol.</i> 2015; <b>33</b>(1): 27–34. <a target=xrefwindow id=d89253e5362 href="http://www.ncbi.nlm.nih.gov/pubmed/25488117">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5365 href="http://dx.doi.org/10.1016/j.tibtech.2014.11.001">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d89253e5374 class=n-a></a>Rath T, Baker K, Dumont JA, <i> et al.</i>: Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. <i>Crit Rev Biotechnol.</i> 2015; <b>35</b>(2): 235–54. <a target=xrefwindow id=d89253e5385 href="http://www.ncbi.nlm.nih.gov/pubmed/24156398">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5388 href="http://dx.doi.org/10.3109/07388551.2013.834293">Publisher Full Text </a> | <a target=xrefwindow id=d89253e5392 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4876602">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718913136"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d89253e5401 class=n-a></a>Andersen JT, Pehrson R, Tolmachev V, <i> et al.</i>: Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. <i>J Biol Chem.</i> 2011; <b>286</b>(7): 5234–41. <a target=xrefwindow id=d89253e5412 href="http://www.ncbi.nlm.nih.gov/pubmed/21138843">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5415 href="http://dx.doi.org/10.1074/jbc.M110.164848">Publisher Full Text </a> | <a target=xrefwindow id=d89253e5419 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3037636">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718913136">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d89253e5432 class=n-a></a>Turecek PL, Bossard MJ, Schoetens F, <i> et al.</i>: PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs. <i>J Pharm Sci.</i> 2016; <b>105</b>(2): 460–75. <a target=xrefwindow id=d89253e5443 href="http://www.ncbi.nlm.nih.gov/pubmed/26869412">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5446 href="http://dx.doi.org/10.1016/j.xphs.2015.11.015">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d89253e5455 class=n-a></a>Strohl WR: Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters. <i>BioDrugs.</i> 2015; <b>29</b>(4): 215–39. <a target=xrefwindow id=d89253e5463 href="http://www.ncbi.nlm.nih.gov/pubmed/26177629">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5466 href="http://dx.doi.org/10.1007/s40259-015-0133-6">Publisher Full Text </a> | <a target=xrefwindow id=d89253e5469 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4562006">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d89253e5479 class=n-a></a>Coppola A, Di Capua M, De Simone C: Primary prophylaxis in children with haemophilia. <i>Blood Transfus.</i> 2008; <b>6</b>(Suppl 2): s4–11. <a target=xrefwindow id=d89253e5487 href="http://www.ncbi.nlm.nih.gov/pubmed/19105503">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5490 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2652217">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d89253e5499 class=n-a></a>Casi G, Neri D: Antibody-drug conjugates: basic concepts, examples and future perspectives. <i>J Control Release.</i> 2012; <b>161</b>(2): 422–8. <a target=xrefwindow id=d89253e5507 href="http://www.ncbi.nlm.nih.gov/pubmed/22306430">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5510 href="http://dx.doi.org/10.1016/j.jconrel.2012.01.026">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d89253e5519 class=n-a></a>Jefferis R: Glycosylation as a strategy to improve antibody-based therapeutics. <i>Nat Rev Drug Discov.</i> 2009; <b>8</b>(8): 226–34. <a target=xrefwindow id=d89253e5527 href="http://www.ncbi.nlm.nih.gov/pubmed/19247305">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5530 href="http://dx.doi.org/10.1038/nrd2804">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d89253e5539 class=n-a></a>Costa AR, Rodrigues ME, Henriques M, <i> et al.</i>: Glycosylation: impact, control and improvement during therapeutic protein production. <i>Crit Rev Biotechnol.</i> 2014; <b>34</b>(4): 281–99. <a target=xrefwindow id=d89253e5550 href="http://www.ncbi.nlm.nih.gov/pubmed/23919242">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5553 href="http://dx.doi.org/10.3109/07388551.2013.793649">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d89253e5562 class=n-a></a>Food and Drug Administration: Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. 2016; <b>2016</b>. <a target=xrefwindow id=d89253e5567 href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm411418.htm">Reference Source</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d89253e5576 class=n-a></a>Food and Drug Administration: Fact Sheet: Breakthrough Therapies. 2016; <b>2016</b>. <a target=xrefwindow id=d89253e5581 href="http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/ucm329491.htm">Reference Source</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d89253e5591 class=n-a></a>Schieppati A, Henter JI, Daina E, <i> et al.</i>: Why rare diseases are an important medical and social issue. <i>Lancet.</i> 2008; <b>371</b>(9629): 2039–41. <a target=xrefwindow id=d89253e5602 href="http://www.ncbi.nlm.nih.gov/pubmed/18555915">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5605 href="http://dx.doi.org/10.1016/S0140-6736(08)60872-7">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d89253e5614 class=n-a></a>Food and Drug Administration: Orphan Drug Regulations: Regulatory History. 2015; <b>2016</b>. <a target=xrefwindow id=d89253e5619 href="http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm356481.htm">Reference Source</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d89253e5628 class=n-a></a>Roger SD: Biosimilars: current status and future directions. <i>Expert Opin Biol Ther.</i> 2010; <b>10</b>(7): 1011–8. <a target=xrefwindow id=d89253e5636 href="http://www.ncbi.nlm.nih.gov/pubmed/20384525">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5639 href="http://dx.doi.org/10.1517/14712591003796553">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d89253e5648 class=n-a></a>Food and Drug Administration: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (Guidance for Industry). 2015; <b>2016</b>. <a target=xrefwindow id=d89253e5653 href="http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf">Reference Source</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d89253e5662 class=n-a></a>Food and Drug Administration: Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product (Guidance for Industry). 2015; <b>2016</b>. <a target=xrefwindow id=d89253e5667 href="http://www.fda.gov/downloads/drugs/guidances/ucm291134.pdf">Reference Source</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d89253e5676 class=n-a></a>Food and Drug Administration: Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 (Guidance for Industry). 2015; <b>2016</b>. <a target=xrefwindow id=d89253e5681 href="http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm444661.pdf">Reference Source</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d89253e5691 class=n-a></a>Food and Drug Administration: Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants (Guidance for Industry). 2015; <b>2016</b>. <a target=xrefwindow id=d89253e5696 href="http://www.fda.gov/downloads/drugs/guidances/ucm345649.pdf">Reference Source</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d89253e5705 class=n-a></a>Food and Drug Administration: FDA approves first biosimilar product Zarxio. 2015; <b>2016</b>. <a target=xrefwindow id=d89253e5710 href="http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm436648.htm">Reference Source</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d89253e5719 class=n-a></a>Food and Drug Administration: FDA approves Inflectra, a biosimilar to Remicade. 2016; <b>2016</b>. <a target=xrefwindow id=d89253e5724 href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm">Reference Source</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d89253e5733 class=n-a></a>Food and Drug Administration: FDA approves Erelzi, a biosimilar to Enbrel. 2016; <b>2016</b>. <a target=xrefwindow id=d89253e5738 href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518639.htm">Reference Source</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d89253e5747 class=n-a></a>Schellekens H, Moors E: Clinical comparability and European biosimilar regulations. <i>Nat Biotechnol.</i> 2010; <b>28</b>(1): 28–31. <a target=xrefwindow id=d89253e5755 href="http://www.ncbi.nlm.nih.gov/pubmed/20062035">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5758 href="http://dx.doi.org/10.1038/nbt0110-28">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d89253e5767 class=n-a></a>Walsh G: Biopharmaceutical benchmarks 2010. <i>Nat Biotechnol.</i> 2010; <b>28</b>(9): 917–24. <a target=xrefwindow id=d89253e5775 href="http://www.ncbi.nlm.nih.gov/pubmed/20829826">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5778 href="http://dx.doi.org/10.1038/nbt0910-917">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d89253e5788 class=n-a></a>Food and Drug Administration: Guidance for Industry: Pharmacogenomic Data Submissions. 2005; <b>2016</b>. <a target=xrefwindow id=d89253e5793 href="http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079849.pdf">Reference Source</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d89253e5802 class=n-a></a>Food and Drug Administration: Guidance for Industry: Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling. 2013; <b>2016</b>. <a target=xrefwindow id=d89253e5807 href="http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm337169.pdf">Reference Source</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d89253e5816 class=n-a></a>Food and Drug Administration: Table of Pharmacogenomic Biomarkers in Drug Labeling. 2016; <b>2016</b>. <a target=xrefwindow id=d89253e5821 href="http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm">Reference Source</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d89253e5830 class=n-a></a>Shankar G, Pendley C, Stein KE: A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. <i>Nat Biotechnol.</i> 2007; <b>25</b>(5): 555–61. <a target=xrefwindow id=d89253e5838 href="http://www.ncbi.nlm.nih.gov/pubmed/17483842">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5841 href="http://dx.doi.org/10.1038/nbt1303">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726558915"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d89253e5850 class=n-a></a>Yin L, Chen X, Vicini P, <i> et al.</i>: Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products. <i>Cell Immunol.</i> 2015; <b>295</b>(2): 118–26. <a target=xrefwindow id=d89253e5861 href="http://www.ncbi.nlm.nih.gov/pubmed/25880103">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5864 href="http://dx.doi.org/10.1016/j.cellimm.2015.03.002">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726558915">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d89253e5877 class=n-a></a>Maertens B, Spriestersbach A, von Groll U, <i> et al.</i>: Gene optimization mechanisms: a multi-gene study reveals a high success rate of full-length human proteins expressed in <i>Escherichia coli</i>. <i>Protein Sci.</i> 2010; <b>19</b>(7): 1312–26. <a target=xrefwindow id=d89253e5891 href="http://www.ncbi.nlm.nih.gov/pubmed/20506237">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5895 href="http://dx.doi.org/10.1002/pro.408">Publisher Full Text </a> | <a target=xrefwindow id=d89253e5898 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2970903">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725087086"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d89253e5908 class=n-a></a>Mauro VP, Chappell SA: A critical analysis of codon optimization in human therapeutics. <i>Trends Mol Med.</i> 2014; <b>20</b>(11): 604–13. <a target=xrefwindow id=d89253e5916 href="http://www.ncbi.nlm.nih.gov/pubmed/25263172">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5919 href="http://dx.doi.org/10.1016/j.molmed.2014.09.003">Publisher Full Text </a> | <a target=xrefwindow id=d89253e5922 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4253638">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725087086">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d89253e5935 class=n-a></a>Hunt R, Sauna ZE, Ambudkar SV, <i> et al.</i>: Silent (synonymous) SNPs: should we care about them? <i>Methods Mol Biol.</i> 2009; <b>578</b>: 23–39. <a target=xrefwindow id=d89253e5946 href="http://www.ncbi.nlm.nih.gov/pubmed/19768585">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5949 href="http://dx.doi.org/10.1007/978-1-60327-411-1_2">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d89253e5958 class=n-a></a>Tsai C, Sauna ZE, Kimchi-Sarfaty C, <i> et al.</i>: Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. <i>J Mol Biol.</i> 2008; <b>383</b>(2): 281–91. <a target=xrefwindow id=d89253e5969 href="http://www.ncbi.nlm.nih.gov/pubmed/18722384">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5972 href="http://dx.doi.org/10.1016/j.jmb.2008.08.012">Publisher Full Text </a> | <a target=xrefwindow id=d89253e5976 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2628389">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d89253e5985 class=n-a></a>Sauna ZE, Kimchi-Sarfaty C: Understanding the contribution of synonymous mutations to human disease. <i>Nat Rev Genet.</i> 2011; <b>12</b>(10): 683–91. <a target=xrefwindow id=d89253e5993 href="http://www.ncbi.nlm.nih.gov/pubmed/21878961">PubMed Abstract </a> | <a target=xrefwindow id=d89253e5996 href="http://dx.doi.org/10.1038/nrg3051">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d89253e6005 class=n-a></a>Houdebine LM: Production of pharmaceutical proteins by transgenic animals. <i>Comp Immunol Microbiol Infect Dis.</i> 2009; <b>32</b>(2): 107–21. <a target=xrefwindow id=d89253e6013 href="http://www.ncbi.nlm.nih.gov/pubmed/18243312">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6016 href="http://dx.doi.org/10.1016/j.cimid.2007.11.005">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727219810"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d89253e6025 class=n-a></a>van Veen HA, Koiter J, Vogelezang CJ, <i> et al.</i>: Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. <i>J Biotechnol.</i> 2012; <b>162</b>(2–3): 319–26. <a target=xrefwindow id=d89253e6036 href="http://www.ncbi.nlm.nih.gov/pubmed/22995741">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6039 href="http://dx.doi.org/10.1016/j.jbiotec.2012.09.005">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727219810">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d89253e6053 class=n-a></a>Hellwig S, Drossard J, Twyman RM, <i> et al.</i>: Plant cell cultures for the production of recombinant proteins. <i>Nat Biotechnol.</i> 2004; <b>22</b>(11): 1415–22. <a target=xrefwindow id=d89253e6064 href="http://www.ncbi.nlm.nih.gov/pubmed/15529167">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6067 href="http://dx.doi.org/10.1038/nbt1027">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d89253e6076 class=n-a></a>Grabowski GA, Golembo M, Shaaltiel Y: Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology. <i>Mol Genet Metab.</i> 2014; <b>112</b>(1): 1–8. <a target=xrefwindow id=d89253e6084 href="http://www.ncbi.nlm.nih.gov/pubmed/24630271">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6087 href="http://dx.doi.org/10.1016/j.ymgme.2014.02.011">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d89253e6096 class=n-a></a>Fox JL: First plant-made biologic approved. <i>Nat Biotech.</i> 2012; <b>30</b>(6): 472. <a target=xrefwindow id=d89253e6104 href="http://dx.doi.org/10.1038/nbt0612-472">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/4252956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d89253e6113 class=n-a></a>Mössner E, Brünker P, Moser S, <i> et al.</i>: Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. <i>Blood.</i> 2010; <b>115</b>(22): 4393–402. <a target=xrefwindow id=d89253e6124 href="http://www.ncbi.nlm.nih.gov/pubmed/20194898">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6127 href="http://dx.doi.org/10.1182/blood-2009-06-225979">Publisher Full Text </a> | <a target=xrefwindow id=d89253e6131 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2881503">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/4252956">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d89253e6144 class=n-a></a>Peters RT, Low SC, Kamphaus GD, <i> et al.</i>: Prolonged activity of factor IX as a monomeric Fc fusion protein. <i>Blood.</i> 2010; <b>115</b>(10): 2057–64. <a target=xrefwindow id=d89253e6155 href="http://www.ncbi.nlm.nih.gov/pubmed/20056791">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6158 href="http://dx.doi.org/10.1182/blood-2009-08-239665">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/720026468"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d89253e6167 class=n-a></a>Dumont JA, Liu T, Low SC, <i> et al.</i>: Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. <i>Blood.</i> 2012; <b>119</b>(13): 3024–30. <a target=xrefwindow id=d89253e6178 href="http://www.ncbi.nlm.nih.gov/pubmed/22246033">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6181 href="http://dx.doi.org/10.1182/blood-2011-08-367813">Publisher Full Text </a> | <a target=xrefwindow id=d89253e6185 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3953019">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/720026468">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/720026512"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d89253e6199 class=n-a></a>Powell JS, Josephson NC, Quon D, <i> et al.</i>: Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. <i>Blood.</i> 2012; <b>119</b>(13): 3031–7. <a target=xrefwindow id=d89253e6210 href="http://www.ncbi.nlm.nih.gov/pubmed/22223821">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6213 href="http://dx.doi.org/10.1182/blood-2011-09-382846">Publisher Full Text </a> | <a target=xrefwindow id=d89253e6217 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3646317">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/720026512">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718872818"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d89253e6230 class=n-a></a>Pelegri-O'Day EM, Lin EW, Maynard HD: Therapeutic protein-polymer conjugates: advancing beyond PEGylation. <i>J Am Chem Soc.</i> 2014; <b>136</b>(41): 14323–32. <a target=xrefwindow id=d89253e6238 href="http://www.ncbi.nlm.nih.gov/pubmed/25216406">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6241 href="http://dx.doi.org/10.1021/ja504390x">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718872818">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d89253e6254 class=n-a></a>Food and Drug Administration: Breakthrough Therapy. 2014; <b>2016</b>. <a target=xrefwindow id=d89253e6259 href="http://www.fda.gov/forpatients/approvals/fast/ucm405397.htm">Reference Source</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d89253e6268 class=n-a></a>Food and Drug Administration: Fact Sheet: Breakthrough Therapies. 2014; <b>2016</b>. <a target=xrefwindow id=d89253e6273 href="http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/ucm329491.htm">Reference Source</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d89253e6282 class=n-a></a>Food and Drug Administration: Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics. 2014; <b>2016</b>. <a target=xrefwindow id=d89253e6287 href="http://www.fda.gov/downloads/Drugs/Guidances/UCM358301.pdf">Reference Source</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d89253e6296 class=n-a></a>Food and Drug Administration: Designating an Orphan Product: Drugs and Biological Products. 2016; <b>2016</b>. <a target=xrefwindow id=d89253e6301 href="http://www.fda.gov/forindustry/developingproductsforrarediseasesconditions/howtoapplyfororphanproductdesignation/default.htm">Reference Source</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d89253e6311 class=n-a></a>Food and Drug Administration: Rare Diseases: Common Issues in Drug Development (Guidance for Industry- Draft). 2015; <b>2016</b>. <a target=xrefwindow id=d89253e6316 href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM458485.pdf">Reference Source</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d89253e6325 class=n-a></a>Food and Drug Administration: Information on Biosimilars. 2016; <b>2016</b>. <a target=xrefwindow id=d89253e6330 href="http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/default.htm">Reference Source</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d89253e6339 class=n-a></a>Moreland L, Bate G, Kirkpatrick P: Abatacept. <i>Nat Rev Drug Discov.</i> 2006; <b>5</b>(3): 185–6. <a target=xrefwindow id=d89253e6347 href="http://www.ncbi.nlm.nih.gov/pubmed/16557658">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6350 href="http://dx.doi.org/10.1038/nrd1989">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d89253e6359 class=n-a></a>Kirk AD, Harlan DM, Armstrong NN, <i> et al.</i>: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. <i>Proc Natl Acad Sci U S A.</i> 1997; <b>94</b>(16): 8789–94. <a target=xrefwindow id=d89253e6370 href="http://www.ncbi.nlm.nih.gov/pubmed/9238056">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6373 href="http://dx.doi.org/10.1073/pnas.94.16.8789">Publisher Full Text </a> | <a target=xrefwindow id=d89253e6377 href="http://www.ncbi.nlm.nih.gov/pmc/articles/23132">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d89253e6386 class=n-a></a>Levisetti MG, Padrid PA, Szot GL, <i> et al.</i>: Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. <i>J Immunol.</i> 1997; <b>159</b>(11): 5187–91. <a target=xrefwindow id=d89253e6397 href="http://www.ncbi.nlm.nih.gov/pubmed/9548454">PubMed Abstract </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d89253e6406 class=n-a></a>Larsen CP, Pearson TC, Adams AB, <i> et al.</i>: Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. <i>Am J Transplant.</i> 2005; <b>5</b>(3): 443–53. <a target=xrefwindow id=d89253e6417 href="http://www.ncbi.nlm.nih.gov/pubmed/15707398">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6420 href="http://dx.doi.org/10.1111/j.1600-6143.2005.00749.x">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2680969"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d89253e6430 class=n-a></a>Vincenti F, Charpentier B, Vanrenterghem Y, <i> et al.</i>: A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). <i>Am J Transplant.</i> 2010; <b>10</b>(3): 535–46. <a target=xrefwindow id=d89253e6441 href="http://www.ncbi.nlm.nih.gov/pubmed/20415897">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6444 href="http://dx.doi.org/10.1111/j.1600-6143.2009.03005.x">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2680969">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d89253e6457 class=n-a></a>Vincenti F, Dritselis A, Kirkpatrick P: Belatacept. <i>Nat Rev Drug Discov.</i> 2011; <b>10</b>: 655–6. <a target=xrefwindow id=d89253e6465 href="http://www.ncbi.nlm.nih.gov/pubmed/21878974">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6468 href="http://dx.doi.org/10.1038/nrd3536">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d89253e6477 class=n-a></a>Pescovitz MD: Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. <i>Am J Transplant.</i> 2006; <b>6</b>(5 Pt 1): 859–66. <a target=xrefwindow id=d89253e6485 href="http://www.ncbi.nlm.nih.gov/pubmed/16611321">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6488 href="http://dx.doi.org/10.1111/j.1600-6143.2006.01288.x">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d89253e6497 class=n-a></a>Reff ME, Carner K, Chambers KS, <i> et al.</i>: Depletion of B cells <i>in vivo</i> by a chimeric mouse human monoclonal antibody to CD20. <i>Blood.</i> 1994; <b>83</b>(2): 435–45. <a target=xrefwindow id=d89253e6511 href="http://www.ncbi.nlm.nih.gov/pubmed/7506951">PubMed Abstract </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d89253e6520 class=n-a></a>Jiang XR, Song A, Bergelson S, <i> et al.</i>: Advances in the assessment and control of the effector functions of therapeutic antibodies. <i>Nat Rev Drug Discov.</i> 2011; <b>10</b>(2): 101–11. <a target=xrefwindow id=d89253e6531 href="http://www.ncbi.nlm.nih.gov/pubmed/21283105">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6534 href="http://dx.doi.org/10.1038/nrd3365">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d89253e6543 class=n-a></a>Nelson AL, Dhimolea E, Reichert JM: Development trends for human monoclonal antibody therapeutics. <i>Nat Rev Drug Discov.</i> 2010; <b>9</b>(10): 767–74. <a target=xrefwindow id=d89253e6551 href="http://www.ncbi.nlm.nih.gov/pubmed/20811384">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6554 href="http://dx.doi.org/10.1038/nrd3229">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d89253e6564 class=n-a></a>Beck A: Biosimilar, biobetter and next generation therapeutic antibodies. <i>MAbs.</i> 2011; <b>3</b>(2): 107–10. <a target=xrefwindow id=d89253e6572 href="http://www.ncbi.nlm.nih.gov/pubmed/21285536">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6575 href="http://dx.doi.org/10.4161/mabs.3.2.14785">Publisher Full Text </a> | <a target=xrefwindow id=d89253e6578 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3092613">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d89253e6587 class=n-a></a>Niwa R, Satoh M: The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology. <i>J Pharm Sci.</i> 2015; <b>104</b>(3): 930–41. <a target=xrefwindow id=d89253e6595 href="http://www.ncbi.nlm.nih.gov/pubmed/25583555">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6598 href="http://dx.doi.org/10.1002/jps.24316">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718262024"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d89253e6607 class=n-a></a>Herter S, Birk MC, Klein C, <i> et al.</i>: Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. <i>J Immunol.</i> 2014; <b>192</b>(5): 2252–60. <a target=xrefwindow id=d89253e6618 href="http://www.ncbi.nlm.nih.gov/pubmed/24489098">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6621 href="http://dx.doi.org/10.4049/jimmunol.1301249">Publisher Full Text </a> | <a target=xrefwindow id=d89253e6625 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3932809">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718262024">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/723903466"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d89253e6638 class=n-a></a>Ferrara C, Grau S, Jäger C, <i> et al.</i>: Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. <i>Proc Natl Acad Sci U S A.</i> 2011; <b>108</b>(31): 12669–74. <a target=xrefwindow id=d89253e6649 href="http://www.ncbi.nlm.nih.gov/pubmed/21768335">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6652 href="http://dx.doi.org/10.1073/pnas.1108455108">Publisher Full Text </a> | <a target=xrefwindow id=d89253e6656 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3150898">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/723903466">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718232166"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d89253e6669 class=n-a></a>Goede V, Fischer K, Busch R, <i> et al.</i>: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. <i>N Engl J Med.</i> 2014; <b>370</b>(12): 1101–10. <a target=xrefwindow id=d89253e6680 href="http://www.ncbi.nlm.nih.gov/pubmed/24401022">PubMed Abstract </a> | <a target=xrefwindow id=d89253e6683 href="http://dx.doi.org/10.1056/NEJMoa1313984">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718232166">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Feb 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-113.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-113.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-113/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 07 Feb 2017, 6:113 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.9970.1">https://doi.org/10.12688/f1000research.9970.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Lagassé HAD <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=10745 data-id=9970 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9970.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-113/v1/pdf?article_uuid=3fb32563-5249-488d-8956-4afa0bd4251f" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.9970.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Lagassé HAD, Alexaki A, Simhadri VL <em>et al.</em> Recent advances in (therapeutic protein) drug development [version 1; peer review: 2 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):113 (<a href="https://doi.org/10.12688/f1000research.9970.1" target=_blank>https://doi.org/10.12688/f1000research.9970.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=9970 id=mobile-track-article-signin-9970 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9970?target=/articles/6-113.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10745 /> <input name=articleId type=hidden value=9970 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Janice Reichert</strong>, The Antibody Society, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Yusuf Tutar</strong>, Division of Biochemistry, Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Cumhuriyet University, Turkey </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Feb 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-113.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-113.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=19878-19529></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=18172-19530></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-113/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>07 Feb 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Janice Reichert</strong>, The Antibody Society, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Yusuf Tutar</strong>, Division of Biochemistry, Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Cumhuriyet University, Turkey </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-113.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-113/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in (therapeutic protein)...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-113/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-113/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-113/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Lagassé HAD et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-113/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-113",
            templates : {
                twitter : "Recent advances in (therapeutic protein) drug development. Lagassé HAD et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-113/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in (therapeutic protein) drug development", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in (therapeutic protein) drug development", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/9970/10745")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "10745");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "19529": 0,
                           "19530": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "9e5c56a2-8e70-45e4-b51b-1830ed8834a9";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-113.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-113.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-113.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-113.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-113.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>